Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 26, 2026.

GABAA receptor-acting neurosteroids: A role in the development and regulation of the stress response

Benjamin G. Gunn, Linda Cunningham, Scott G. Mitchell and 3 more

Frontiers in Neuroendocrinology · 2015 · Review · CC BY

doi:10.1016/j.yfrne.2014.06.001

Abstract

Regulation of hypothalamic-pituitary-adrenocortical (HPA) axis activity by stress is a fundamental survival mechanism and HPA-dysfunction is implicated in psychiatric disorders. Adverse early life experiences, e.g. poor maternal care, negatively influence brain development and programs an abnormal stress response by encoding long-lasting molecular changes, which may extend to the next generation. How HPA-dysfunction leads to the development of affective disorders is complex, but may involve GABAA receptors (GABAARs), as they curtail stress-induced HPA axis activation. Of particular interest are endogenous neurosteroids that potently modulate the function of GABAARs and exhibit stress-protective properties. Importantly, neurosteroid levels rise rapidly during acute stress, are perturbed in chronic stress and are implicated in the behavioural changes associated with early-life adversity. We will appraise how GABAAR-active neurosteroids may impact on HPA axis development and the orchestration of the stress-evoked response. The significance of these actions will be discussed in the context of stress-associated mood disorders.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Stress, GABAA receptors and neurosteroids

Stressful experiences engage a co-ordinated neuronal and hormonal response, orchestrated by the hypothalamic–pituitary–adrenocortical (HPA) axis via activation of corticotrophin releasing factor (CRF)-releasing parvocellular neurones of the hypothalamic paraventricular nucleus (PVN). The activity of the PVN is subject to regulation by GABA, the dominant inhibitory neurotransmitter in the hypothalamus, which acts primarily via GABAA receptors (GABAARs). The neurocircuitry regulating the activity of the PVN is highly complex, comprised of mono- and polysynaptic inputs from a number of different limbic and forebrain regions. GABAARs are expressed throughout this circuit where they play an important role in modulating the functional activity, and hence output, of these brain regions. Thus, regulation of HPA axis activity through GABAAR-mediated transmission not only occurs at the level of the PVN, but also at multiple levels of the stress neurocircuitry.

GABAARs possess a pentameric structure formed from multiple subunits. To date, 19 subunits have been identified (α1-6, β1-3, γ1-3, δ, ε, θ, π and ρ1-3), which are divided into subfamilies based upon their amino acid homology. These subunits exhibit discrete expression profiles, allowing for the expression of ∼20–30 different GABAAR isoforms within the CNS with most native receptors comprising two α, two β and a single γ, δ or ε subunit. Importantly, GABAAR isoforms containing the γ subunit are generally, albeit not exclusively (e.g. α5βγ2 isoforms) targeted to synapses where they mediate “phasic” GABAergic transmission, while δ-GABAARs comprise a major class of peri- and extrasynaptic receptors that mediate a “tonic” and “spill-over” form of GABAergic inhibition. The subunit composition not only determines the regional and cellular location of GABAARs, but also influences their biophysical and pharmacological profile. For example, incorporation of the γ2 subunit in conjunction with specific α subunits (α1-3 and α5) conveys benzodiazepine (BDZ) sensitivity.

Modulation of GABAAR function by endogenous ligands may provide a physiologically and pathologically relevant mechanism to regulate GABAAR-associated functions and behaviour. In this respect, the positive allosteric actions of some endogenously occurring steroids have been identified to be of particular physiological and pharmacological significance over the course the past 3 decades. Specifically, following the pioneering discovery of the GABAAR potentiating actions of the synthetic anaesthetic steroid, Alphaxalone (5α-pregnan-3α-ol-11,20-dione ) certain endogenous steroids, synthesised de novo in the brain and hence called neurosteroids were shown to share this property. Such neurosteroids include the progesterone (PROG) metabolites 5α-pregnan-3α-tetrahydroprogesterone (5α3α-THPROG), 5β-pregnan-3α-tetrahydroprogesterone (5β3α-THPROG) and the deoxycorticosterone (DOC) metabolite 5α,3α-tetrahydrodeoxycorticosterone (5α3α-THDOC), which in common potently and stereo-selectively enhance GABAAR function in an allosteric fashion. Intriguingly, the levels of such neurosteroids are rapidly elevated following acute stress and therefore, they may act to “fine-tune” the function of GABAARs and consequently influence HPA axis activity. In support, neurosteroids inhibit CRF release and exhibit anxiolytic and stress-protective properties.

Electrophysiological recordings have demonstrated that neurosteroids, such as 5α3α-THPROG and 5α3α-THDOC, potentiate the response of GABA (i.e. GABA-modulatory) at nanomolar aqueous concentrations, whilst at higher concentrations these endogenous regulators directly activate (i.e. GABA-mimetic) the GABAAR-channel complex. A significant body of evidence consistent with the presence of a specific neurosteroid binding site on the receptor has been provided during the past 25 years including: modulation of [3H] muscimol binding in solubilised preparations with minimal lipid content; clear enantioselectivity and antagonism of both the in vitro and in vivo actions of neurosteroids by selective ligands i.e. 3α5α-17-phenylandrost-16-en-3-ol (17PA – ). A more definitive validation arose from site-directed mutagenesis studies, which revealed that neurosteroids interact with two distinct groups of amino acid residues located within the transmembrane (TM) domains of the GABAAR, which are both critical for their GABA-modulatory and the GABA-mimetic actions. Subsequent reports have indicated that the neurosteroid binding pocket may possess a more complex structure than initially suggested with additional amino acid residues contributing to the modulatory actions of distinct, but structurally related steroid molecules. Note that in vitro electrophysiological studies consistently report neuroactive steroids such as 5α3α to enhance GABAAR function at nM aqueous concentrations, suggesting the presence of a relatively high affinity binding site on the GABAAR protein. However, by virtue of their high lipid solubility, the actual concentration of neurosteroid achieved locally at the receptor protein will be in the micromolar range. Indeed, the differential accumulation of these steroids within the lipid membrane may serve to increase their local concentration, a suggestion which is in accord with a putative transmembrane docking site for neurosteroids. Such a scenario would enable and indeed facilitate neurosteroid access to a relatively low affinity binding site(s) located within the transmembrane spanning regions of the protein, via lateral diffusion through the membrane bilayer.

A variety of factors have been shown to influence the apparent sensitivity of native GABAARs to neurosteroid modulation, including the subunit composition, phosphorylation state of the receptor and local steroid metabolism. A detailed discussion of the relative contribution by each of these molecular mechanisms can be found in recent reviews.

Importantly, from a physiological perspective, naturally occurring plasma and brain levels of neurosteroids are estimated to be within a range required to potentiate GABAAR function. Further, the synthesis of these neuromodulators is dynamically regulated in response to physiological and pathophysiological challenges e.g. stress thus supporting the proposal for a significant role as endogenous regulators of GABAAR-mediated inhibitory transmission both in the central (CNS) and peripheral nervous system (PNS). In this review we will specifically appraise and focus on the documented and potential relevance of such actions for the early programming of the stress-neurocircuit and the regulation of stress-evoked responses. The potential pathological significance of such actions for stress-associated psychopathology will also be discussed.

Neuronal and glia-mediated synthesis of neurosteroids

Although a significant proportion of neurosteroids are derived from peripheral sources, such as the adrenal cortex and ovaries, the brain itself is a steroidogenic organ that is capable of the de novo synthesis of these neuromodulators. Neurosteroids are synthesised from cholesterol via a series of steps that include the translocation of cholesterol across the mitochondrial membrane by the steroidogenic acute regulatory protein (StAR) and translocator protein 18 kDa (TSPO; formerly the mitochondrial peripheral BDZ receptor), the rate limiting step of steroid and neurosteroid synthesis. Within the mitochondria, cholesterol is converted to pregnenolone (PREG) by the P450 side-chain cleavage enzyme, CYP11A1 and then trafficked to the cytoplasm where it can be converted to a number of neurosteroids known to be active at the GABAAR, including 5α3α-THPROG. PREG is converted to 5α3α-THPROG following three sequential reactions catalysed by 3β-hydroxysteroid dehydrogenase (3β-HSD), 5α-reductase (5α-R) and 3α-hydroxysteroid dehydrogenase (3α-HSD), with progesterone and 5α-dihydroprogesterone (5α-DHP) being the respective intermediates. Two of these enzymes, 5α-R and 3α-HSD, are also involved in the conversion of the peripherally derived glucocorticoid metabolite, deoxycorticosterone (DOC) into 5α3α-THDOC (Fig. 1 – ). Although a detailed discussion is beyond the scope of this review (but see ), two isoforms of 5α-R (type I and II) exist. While type I is the most abundant in both human and rodent brain, type II can be hormonally (e.g. testosterone) induced.

A variety of brain cells have been shown to synthesise neurosteroids. Early studies described a role for astrocytes and glia in neurosteroidogenesis. However, more recent immunohistochemical studies have suggested that the synthetic machinery necessary for neurosteroidogenesis, including StAR, CYP11A1, 3α-HSD and 5α-R, is highly expressed in excitatory principal cells in a number of brain regions, including the hippocampus and cortex (see Fig. 1 for details). Furthermore, immunohistochemical analysis of 5α3α-reduced pregnane steroid (e.g. 5α3α-THPROG, 5α3α-THDOC) localization within the brain, has detected the expression only in the cell bodies and dendrites of excitatory (glutamatergic) and, to a lesser extent, inhibitory (GABAergic) neurones in a brain region specific manner (e.g. ). Such observations are consistent with the proposed paracrine or indeed autocrine role of neurosteroids to locally regulate GABAAR-mediated inhibition. Although there is significant evidence to suggest a neuronal synthesis of neurosteroids, it is noteworthy that TSPO, the rate limiting step in steroid and neurosteroid synthesis ( – see Section 2.2), is highly expressed in glia, microglia and reactive astrocytes with only limited neuronal expression. Thus, it seems highly likely that, as originally postulated, glia are involved, at least to a degree, in the de novo synthesis of neurosteroids from cholesterol.

Local neurosteroid regulation of GABAAR function: physiological and pharmacological relevance

Recent experimental evidence provides considerable support to the notion that locally produced neurosteroids can enhance GABAergic transmission, and hence modulate neuronal excitability. Typically, the effect of these neuromodulators at synaptic and extrasynaptic GABAARs is manifest as a prolongation of the decay time of inhibitory post-synaptic currents (IPSCs) and as an increase in the tonic conductance respectively. Pharmacological manipulation of brain steroidogenesis has proved a useful strategy in elucidating the influence of local neurosteroid production upon shaping inhibitory transmission in specific neuronal populations. Thus, inhibition of 5α-reductase activity with the antagonist SKF105111 (11β-17-[bis(1 methylethyl) amino carbonyl – Fig. 1], resulted in a reduction in the decay time constant of spontaneous inhibitory post-synaptic currents (sIPSCs) recorded from neocortical pyramidal cells derived from the SKF-treated cf saline treated mice, indicating the presence of an endogenous neurosteroid tone in these neurones. In the hippocampus, miniature IPSCs (mIPSCs) recorded from dentate gyrus granule cells (DGGCs) were more sensitive to prolongation by the metabolically stable synthetic steroid analogue, ganaxalone (3β-methyl-5α3α-THPROG) in comparison to 5α3α-THPROG, raising the possibility that neurosteroid metabolism may be responsible for this differential sensitivity. In particular, 3α-HSD, unlike 5α-reductase, is involved in both the synthesis and degradation of 5α3α-THPROG (and 5α3α-THDOC) as the cytosolic isoform catalyses the reductive formation of 5α3α-THPROG from 5α-dihydroprogesterone (5α-DHP), whilst the membrane bound isoform promotes the reverse, oxidative reaction ( – Fig. 1). Interestingly, in the dentate gyrus (DG) the membrane-bound isoform is prevalent and the inhibition of this enzyme with indomethacin, or methoxyprogesterone acetate (Provera – Fig. 1) resulted in a modest increase in both the mIPSC decay time constant and the bicuculline-sensitive tonic conductance, whereas CA1 GABAAR-mediated transmission remained unaffected by similar manipulations Furthermore, the treatment of brain slices with indomethacin or Provera alone enhanced the sensitivity of DGGCs to exogenously applied 5α3α-THPROG (100 nM, ). Collectively, these observations indicate that the relative activity of 3α-HSD isoforms can influence the concentration of neurosteroids GABAARs experience and hence, may play a crucial role in shaping inhibitory transmission in a neurone, or even synapse, specific manner.

As described above, the translocator protein 18 kDa (TSPO) is located on the outer mitochondrial membrane, and in conjunction with the steroidogenic acute regulator protein (StAR, ) mediates the translocation of cholesterol across the outer mitochondrial membrane, the initial, and rate limiting step of steroid and neurosteroid synthesis. Thus, provided a neurone contains the full complement of functionally active steroidogenic enzymes required for the de novo synthesis of 3α-reduced neurosteroids, then the stimulation of TSPO-mediated cholesterol translocation should increase the level of neurosteroids. Indeed, etifoxine is an anxiolytic drug that not only acts as a positive allosteric modulator of GABAAR function, but also stimulates TSPO to increase the cerebral production of 5α3α-THPROG, an effect that contributes to the behavioural actions of this drug. More recent studies, in neurones from the mouse medial prefrontal cortex (mPFC), demonstrated that the selective TSPO ligand XBD173 (N-benzyl-N-ethyl-2-[7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl] acetamide) produces an enhancement of the amplitude and duration of evoked IPSCs (eIPSCs) and mIPSCs. These effects were blocked by the 5α-reductase inhibitor, finasteride. In addition, XBD173 is effective in rodent behavioural tests predictive of anxiolytic action, and these actions are attenuated by the TSPO antagonist PK11195 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; ]. Importantly, the anxiolytic actions of XBD173 extend to human subjects, adding further credence to the proposal that compounds selectively targeting TSPO may provide novel anxiolytic agents with a reduced side effect profile.

The treatment of brain slices with neurosteroid precursors such as PROG and DHP, have proved useful in establishing the steroidogenic potential of specific neurones. For example, in hippocampal CA1 pyramidal neurones, the inhibition of 5α-reductase with finasteride had no effect upon the decay time course of mIPSCs. However, the bath application of the 5α-reductase substrate, PROG (1 μM) resulted in a slowly developing, and finasteride-sensitive prolongation of the mIPSC decay kinetics. Such observations may suggest that although CA1 pyramidal neurones do not exhibit a constitutive neurosteroid tone, the enzymes required for neurosteroidogenesis (i.e., 5α-reductase, 3α-HSD) are functionally expressed within these neurones. However, PROG had no effect upon the hippocampal expression of the 3α-HSD gene in either gender thus suggesting the lack of a simple correlation with precursor substrate levels. Whilst the specific molecular mechanisms regulating enzymes gene expression and function remain to be fully elucidated, of significance, a recent study in rodent hippocampal CA1 pyramidal neurones has revealed activation of NMDA receptors (NMDARs) to rapidly promote neurosteroid synthesis via a signalling mechanism involving p38 mitogen-activated protein kinase (MAPK), neuronal nitric oxide synthase and calcineurin. Thus, NMDARs may play a pivotal role in the regulation of neurosteroidogenesis, potentially linking initial neural excitation to enhancement of neuronal inhibition.

In addition to a physiological role as regulators of GABAergic transmission, neurosteroids have been implicated in the pharmacological actions of a range of structurally diverse drugs acting on the GABAA receptors. Thus, several line of evidence have implicated neurosteroids in some of the electrophysiological and behavioural effects associated with ethanol administration. For example, the acute application of ethanol to CA1 pyramidal neurones promoted synthesis of 5α3α-THPROG resulting in an augmented peak amplitude and a prolonged decay time course of the mIPSCs recorded from such neurones. Furthermore, in rats, acute ethanol treatment completely blocked the induction of hippocampal long-term potentiation (LTP), an effect dependent upon NMDAR-induced neurosteroid synthesis and, in agreement, sensitive to inhibition by either finasteride or the NMDAR antagonist AP-5.

Similarly, the effects of certain clinically important benzodiazepines (BDZs) may be mediated by (i) binding directly to the GABAAR (at a site between the α and γ subunits) to allosterically and rapidly enhance receptor function and (ii) activating TSPO to produce a delayed indirect enhancement of receptor function by increasing neurosteroid production. The best characterised BDZs which exhibit potentially pharmacologically relevant affinity for TSPO and the GABAAR include diazepam and midazolam, whereas the potent GABAAR-acting BZD clonazepam is a weak TSPO ligand. Evidence that both molecular targets may contribute to the pharmacological actions of such ligands has been offered by various independent investigations. Thus, for example, midazolam, a BDZ used clinically to facilitate the induction of anaesthesia, increased neurosteroid levels in CA1 pyramidal neurones and prevented the induction of LTP, a molecular correlate of memory function, in an acute brain slice preparation. Implicating neurosteroids, inhibiting their synthesis with finasteride, or preventing the GABA-modulatory actions of neurosteroids with the selective antagonist 17PA attenuated the midazolam-induced impairment of LTP, consistent with a role for neurosteroidogenesis in the documented amnestic actions of this BDZ. In agreement with these in vitro findings, finasteride pre-treatment 1 day prior to midazolam injection, completely abolished the effects of this BDZ upon contextual fear learning. Similarly, midazolam exhibited a clear anticonvulsant action in the i.v. PTZ threshold model, which was significantly attenuated by finasteride treatment. In contrast, clonazepam, an anxiolytic and anticonvulsant BDZ, did not induce changes in hippocampal neurosteroid synthesis, and had no effect upon LTP induction. However, consistent with a role for neurosteroidogenesis in the attenuation of LTP induction, when administered with the TSPO agonist FGIN (2-[2-(4-fluorophenyl-1H-indol-3-yl), or together with exogenous 5α3α-THPROG, clonazepam induced similar LTP-impairing effects to midazolam. However, the clinical relevance of midazolam actions have been questioned by a recent PET study suggesting the TSPO occupancy by clinically relevant concentrations of midazolam to be too low to contribute to the BZD in vivo profile in humans. Therefore some caution may need to be exercised when extrapolating findings from rodent studies to humans.

The stress circuitry and a role for GABAARs in the stress response

Maintaining physiological homeostasis in response to environmental and physiological challenges is essential for an organism to survive and such an ability to adapt is mediated through a number of tightly regulated and highly conserved interconnected systems. The hypothalamic paraventricular nucleus (PVN) is a brain region that is integral in the initiation of the neuroendocrine and autonomic response to a stressful challenge. Following stressor exposure, spinally projecting parvocellular neurones (located in dorsal and ventromedial regions) of the PVN rapidly modulate autonomic function, whilst neuroendocrine parvocellular neurones (located in dorsomedial regions), project to the median eminence and initiate activation of the HPA axis through the release of CRF. The HPA axis is a neuroendocrine pathway that couples the CNS to the periphery, and is regulated via hormonal feedback pathways (e.g. glucocorticoid, CRF) and a complex neurocircuitry comprised of mono- and polysynaptic pathways. As noted earlier, GABA has been identified as the dominant inhibitory neurotransmitter within the PVN and, in agreement, exerts a significant inhibitory tone upon HPA axis function. Tract tracing studies in rodents have revealed the majority of the GABAergic afferents to the PVN to originate from a number of local hypothalamic nuclei (e.g. peri-PVN, dorsomedial hypothalamus, anterior hypothalamus, preoptic area as well as regions of the extended amygdala (e.g. bed nucleus of the stria terminalis, BST – Fig. 2). Limbic and forebrain regions (e.g. ventral subiculum, medial prefrontal cortex and amygdala) also exert significant influence upon HPA axis activity, but do not directly innervate the PVN. Rather, these limbic and forebrain structures modulate HPA axis function via projections to a number of the local GABAergic nuclei, in particular regions of the BST ( – Fig. 2) and peri-PVN, which act as neural hubs to integrate and relay limbic and forebrain influences upon HPA function to the PVN ( – Fig. 2).

The GABAergic inhibitory tone is balanced by a comparable excitatory input to the PVN, which is heavily innervated by excitatory glutamatergic terminals. Retrograde fluorogold labelling has revealed glutamatergic inputs to originate from regions of the ventromedial and dorsomedial hypothalamus and to co-exist with local interneurons within the PVN, in contrast to GABAergic inputs, which derive exclusively from peri-PVN regions. In support, in situ hybridization studies have revealed within the PVN the expression of multiple ionotropic glutamate receptor subunits, particularly of the NMDA receptor family. In agreement, spontaneous action current firing of mpd neurones is abolished following the bath application of ionotropic glutamate receptor antagonists e.g. kynurenic acid, or AP-5 and DNQX while intra-PVN microinjections of kynurenic acid significantly reduced glucocorticoid release following exposure to acute restraint stress. Collectively these findings support a primary role for glutamate in driving the excitability of these neurones.

Within the medial parvocellular region of the PVN, quantitative ultrastructural analysis has revealed that CRF-releasing neurones are the principle recipient of GABAergic inputs and dual in situ hybridization and immuohistochemical studies have demonstrated the expression of multiple GABAAR subunits (e.g. α1, α2, α3, α5, β1-3 and γ1, γ2) in the majority of these neurones ( – Fig. 1). In support, the GABAAR antagonist, bicuculline, increases the frequency of action current firing of rodent mpd CRF-releasing neurones and in agreement, plasma corticosterone levels increase, or decrease following the in vivo microinjection of bicuculline and muscimol respectively into the PVN.

The observations summarised above indicate that the balance between glutamatergic and inhibitory GABAergic transmission plays a fundamental role in regulating the output of the HPA axis. As a corollary to this suggestion, modulation of GABAAR function by endogenous neurosteroids may be important in “fine tuning” HPA axis function. The following section will review evidence in support of such a proposal and the relevance of these effects to the anxiolytic actions of neurosteroids.

Stress and neurosteroids

The anxiolytic actions of the endogenous neurosteroid 5α3α-THDOC were demonstrated almost 30 years ago. However it was not until the pioneering studies by Bob Purdy in the early 1990s revealed that the brain levels of 5α3α-THDOC and 5α3α-THPROG were rapidly elevated in the rodent cortex and hypothalamus following exposure to acute swim stress that a putative role for neurosteroids as regulators of the stress response was postulated. Of specific significance, adrenalectomy prevented the stress-induced increase in 5α3α-THDOC, but not 5α3α-THPROG, demonstrating the de novo brain synthesis of the latter neurosteroid. Such observations suggested that neurosteroids synthesised de novo within the CNS and those derived from peripheral sources may be important modulators of the behavioural and/or neuroendocrine response to stress. Pertinent to such a hypothesis, the steroid synthesising enzymes, 5α-reductase and 3α-HSD are expressed within the hypothalamus, while 5α3α-THPROG immunoreactivity can be detected within the extended amygdala and hypothalamus. Furthermore, several investigations have demonstrated similar increases in neurosteroid levels in response to a range of different stressors, while the administration of 5α3α-THPROG and 5α3α-THDOC produce anxiolytic effects in various test of anxiety in rodents. In further support, administration in rats of progesterone or agonists of TSPO induced increased levels of 5α3α-THPROG within the brain, which associated with anxiolytic-like effects that are attenuated by inhibitors of 5α-reductase or GABAAR antagonists.

The release of CRF from hypothalamic neuroendocrine parvocellular neurones triggers the activation of the HPA axis and i.c.v. injection of this neuropeptide induces behaviours similar to those associated with stress and anxiety. Interestingly, the anxiogenic effects of CRF in rats exposed to the elevated plus maze (EPM) can be prevented in a dose-dependent manner by pre-treatment with 5α3α-THPROG. Furthermore, the pre-treatment of rats with 5α3α-THPROG, 5α3α-THDOC or PROG significantly attenuates the stress-induced increase in plasma ACTH and corticosterone. Consistent with such in vivo actions, 5α3α-THPROG also suppresses the methoxamine [an α1-adrenoreceptor (α1-AR) agonist]-induced release of CRF in hypothalamic explant preparations, while having no effect upon basal release of this neuropeptide. Such an effect is compatible with an action upon GABAAR as enhancement of the GABAergic tone similarly inhibits CRF release from parvocellular neurones. Congruent with such a proposal, in electrophysiological recordings made from neonatal (P18-26) mouse hypothalamus, we find that low concentrations (10–100 nM) of 5α3α-THPROG enhance GABAAR-mediated synaptic transmission of CRF-releasing mpd neurones of the PVN and inhibit their output. Furthermore, low concentrations of the DOC metabolite, 5α3α-THDOC, similarly reduces the output from neuroendocrine and spinally projecting parvocellular neurones. The relevance of these studies in rodents to the regulation of the stress response in humans is emphasised by the demonstration that 5α-THDOC plasma levels exhibit a robust increase in response to a cholecystokinin-tetrapeptide (CCK-4)-induced panic attack in healthy volunteers. This increase is concomitant to stimulation of ACTH and cortisol release, both hallmarks of HPA axis activation, thus suggesting a specific possible role for 5α-THDOC in the termination of the stress/anxiety response following the CCK-4 challenge.

Collectively, the evidence gathered from molecular, immunohistochemical, electrophysiological and behavioural studies strongly supports the notion that endogenous 3α-reduced neurosteroids can reduce HPA axis activity by enhancing GABAAR function and such an action is consistent with their anxiolytic-like profile. Amongst the specific molecular targets mediating the actions of neurosteroids, the expression of α2-GABAAR in the PVN (see Section 3.1 and Fig. 1) may be of particular significance for their anxiolytic and stress-protective actions (Fig. 1). In agreement with this suggestion, in a recent report, “knock-in” mice, expressing a neurosteroid-insensitive α2 subunit (α2Q241M), exhibit an anxiogenic phenotype and an impairment of the anxiolytic response to injected neurosteroid, indicating a functional relevance. Moreover, α2-containing GABAARs have been shown to mediate the anxiolytic action of classical BDZ’s, such as diazepam and are highly expressed not only in PVN, where the mRNA for the α2-subunit is highly co-localised with CRF mRNA signal, but also in other stress-sensitive brain regions including the amygdala, hippocampus and nucleus accumbens. Moreover, coupled with the inhibition of CRF, ACTH and corticosterone release by 5α3α-THPROG described above, this finding is consistent with the suggestion that potentiation of α2-GABAAR isoforms may specifically contribute to the anxiolytic profile of neurosteroids.

Recently, the reported shift in the polarity of GABA actions (from hyperpolarising to depolarising) in neuroendocrine parvocellular neurones upon exposure to acute restraint stress has led to the proposal that stress-induced modulation of GABAergic transmission by 5α3α-THDOC may actually facilitate rather than restrain activation of the HPA axis. Although such a scenario may be plausible, it does not appear compatible with their well-documented anxiolytic-like properties and the inhibitory actions of 5α3α-THPROG upon CRF, ACTH and corticosterone release as discussed above. Furthermore, the temporal profiles of the observed changes in GABAergic transmission and behavioural parameters on one side, and the stress-induced increase in neurosteroid levels on the other appear incongruent with a facilitatory effect of neurosteroid upon HPA axis activation. Thus, a decrease in GABAergic transmission and comparable changes in behavioural parameters related to GABAergic transmission occur rapidly (within ∼5 min) and with a similar time course following stressor exposure. However, the levels of neurosteroids peak both in the whole brain and in the hypothalamus with a delay of ∼30–60 min after a stressful challenge, a time course mimicked by inducing stress by the direct injection of CRH, or ACTH. This temporal profile parallels the manifestation of their anxiolytic-like properties, a synchrony that appears incompatible with a facilitation of HPA axis activity.

In further albeit indirect support, the effect of stress on neurosteroid levels is mimicked by treatment with an anxiogenic GABAAR acting ligand but antagonized by anxiolytic benzodiazepines. Thus, neurosteroids appear to act in an adaptive fashion to curtail the extent and duration of the stress-induced inhibition of GABAergic transmission. Nevertheless, as noted above, other stress-sensitive regions implicated in the regulation of emotional states, e.g. hippocampus and amygdala, will contribute their anxiolytic properties.

Programing of the stress neurocircuitry: a role for endogenous neurosteroids?

Throughout the lifespan, exposure to physiological and environmental challenges can have profound and enduring effects upon stress susceptibility and resilience. However, in mammals, the pre- and post-natal periods appear particularly critical for brain development, and stressor exposure at this stage can severely alter physiological, behavioural and cognitive functions during adolescence and adulthood. The following section will introduce how early postnatal experiences can modulate neurodevelopment with an emphasis on (1) the potential role for endogenous neurosteroids in the maturation of the HPA axis and overall stress neurocircuitry and (2) the impact of early-life adversity upon the stress-protective actions of endogenous neurosteroids. For a detailed discussion on the role of prenatal experience and specifically stress on programming of the HPA axis, see recent reviews.

Early-life experience and HPA maturation

In rodents, the early postnatal period, is characterised by a marked hyporesponsivity of the HPA axis, occurring during days 4–14 of life. This ‘hyporesponsive’ period coincides with stages of axonal growth, synaptogenesis and myelination within key brain neurocircuits, and as such it has been postulated that the dampening of HPA axis reactivity, via a pituitary-mediated mechanisms involving GR inhibition of ACTH release, is an important mechanism for protecting the developing brain from excessive levels of glucocorticoids. Interestingly, alterations in the activation of limbic and forebrain GABAergic circuits have been implicated as potential candidates underlying reduced HPA function during the stress hyporesponsive period. The mother–pup interaction in rodents is crucial for the maturation of the HPA axis, and alterations in the level of maternal behaviours, such as licking-grooming (LG) and arched back nursing (ABN) can significantly influence the behavioural and neuroendocrine response to stress in adulthood. Specifically, the adult offspring of high-compared to low-LG-ABN mothers exhibited decreased levels of hypothalamic CRF mRNA and increased hippocampal GR mRNA expression, which was accompanied by an increased sensitivity to glucocorticoid feedback and more modest HPA responses to acute stress. Interestingly, cross-fostering studies have revealed that these variations in maternal care may serve as a mechanism for the non-genomic transmission of individual differences in stress reactivity across generations e.g. via epigenetic mechanisms. The subsequent finding that alterations in hippocampal GR expression associated with differing levels of maternal care were caused by differences in DNA methylation of the GR gene promoter region and alterations in histone acetylation provided the first demonstration that maternal care can indeed modify the epigenomic state of stress-related genes. Moreover, these observations identified epigenetic modifications as candidate mechanisms to mediate gene-environment interactions that impact upon the maturation of the stress axis.

Experimentally-induced manipulations to either enhance or impair maternal care have proved useful approaches to investigate the mechanisms underlying the neurobiological plasticity associated with early-life experience and maturation of the HPA axis (reviewed in ). For example, in rodents, postnatal handling comprising of short periods (i.e. 3–15 min) of daily separation of the pups from their mother during the first week(s) of life, promotes increased active maternal behaviours (i.e. LG, ABN) following the return of the pups to the home cage. Similar to pups exposed to high levels of maternal care, early handling has been shown to result in decreased stress reactivity in adulthood, reduced hypothalamic CRF expression and increased hippocampal GR. In contrast, adult offspring exposed to longer recurrent daily periods of maternal separation (e.g. 2–3 h) during the early postnatal period (e.g. P2-P14) displayed a significantly increased HPA response to acute stress, which was accompanied by a reduction in the expression of hippocampal GR mRNA and increased CRF mRNA in the hypothalamic PVN ( although see ). Interestingly, in a model of augmented maternal care, reprogramming of the stress response is mediated early-on (by P9) by a decreased expression of CRF in neurones of the PVN and only at later developmental stages by a reduced hormonal response to stressor exposure (by P23) and an epigenetically-induced enhancement of hippocampal GR expression (to increase the GR negative feedback), which takes place between P23-P45. Such observations suggest that plasticity of hypothalamic CRF-releasing neurones, resulting in the suppression of crh gene expression, is an early and potentially important process in the mechanism(s) responsible for mediating the effects of increased maternal care upon the stress response. Although not yet elucidated, it seems plausible that a similar temporal profile may be associated with the alterations in hypothalamic CRF, endocrine stress response and hippocampal GR expression that accompany negative early life experience (e.g. maternal separation, or fragmentation – see below).

Neurosteroids and HPA development

A potential physiological role for neurosteroids in the programming of the stress response was first proposed following the observation that administration of 5α3α-THPROG reduced the number of ultrasonic vocalisations (USVs), a measure of an anxious-like phenotype, in neonatal rat pups (P7) previously exposed to maternal separation. In support, in adult rats, the behavioural and neuroendocrine effects of repeated maternal separation early in life (P2-P10) were attenuated when 5α3α-THDOC was concomitantly administered during the separation period. Consistent with a putative physiological role of neurosteroids early in life, the levels of 3α-HSD mRNA are elevated in the dentate gyrus of male and female rats at P7. Interestingly, the behavioural and neuroendocrine dysregulation associated with maternal separation in rats shows a gender specific profile as adult male, but not female rats displayed an anxious phenotype on the EPM following maternal separation (P5-P6; ), although such effects may be additionally dependent upon the maternal separation protocol used. These sex-specific effects are likely to be a consequence of increased peripherally derived steroids (e.g. estrogen, progesterone) in females, as overectomised (OVX) female rats exposed to maternal separation exhibited an anxious-like phenotype on the EPM comparable to that observed in males. Interestingly, however, the concomitant administration of 5α3α-THPROG during maternal separation attenuated the behavioural and neuroendocrine consequences associated with postnatal stress in both genders. Similar gender-specific regulation of neurosteroidogenesis has been described for the mPFC where restrain stress increased the mRNA and protein levels of 5α-reductase more significantly in male compared to female rats.

More recent studies have revealed that elevating the levels of neonatal (P5) 5α3α-THPROG altered exploratory and anxiety-like behaviours in adulthood, while reducing neurosteroid levels with the 5α-reductase inhibitor, finasteride produced an anxiogenic-like phenotype.

The molecular mechanisms whereby neonatal levels of neurosteroids may regulate maturation of the HPA axis remain to be identified but the observation that during the first postnatal week activation of GABAAR mediates a depolarising response and thus may lead to secondary Ca2+ influx to trigger second-messenger-mediated changes in gene expression or protein function offers scope for future investigations (Fig. 4).

Neuroplasticity of the PVN

The observation that a reduction in hypothalamic CRF expression precedes the reduced hormonal stress response and the epigenetically augmented expression of hippocampal GRs accompanying early handling suggests that plasticity of the hypothalamic CRF-releasing neurone is an early and important component of experience-induced programming of the stress response. Therefore, understanding the molecular and functional changes that occur in these neurones in response to variable maternal sensory inputs has been the focus of recent research. As described above (Section3.1) CRF-releasing neurones of the PVN receive excitatory glutamatergic, and inhibitory GABAergic inputs that signal via glutamate and GABAA receptors respectively. Thus, recent studies have investigated whether augmented maternal care induces alterations in excitatory and inhibitory inputs to these neurones. A combined approach of quantitative confocal microscopy, electron microscopy and electrophysiology, has revealed augmented maternal care to associate with a significant and selective reduction in the number of glutamatergic but not GABAergic synapses onto CRF neurones. This neuroplasticity in excitatory transmission is accompanied by an increased expression of the transcriptional repressor neuron-restrictive silencing factor (NRSF), which negatively regulates crh gene transcription. Interestingly, although the reduced excitatory drive onto CRF-releasing neurones dissipated by adulthood, the elevated NRSF levels and suppression of CRF expression were preserved, suggesting that reduced glutamatergic transmission in the developing PVN though crucial to initiate the reprogramming of CRF expression, is not necessary for its maintenance. In support of such a notion, recent studies using hypothalamic neuronal cultures have revealed that pharmacological blockade of ionotropic glutamate receptors is sufficient to down-regulate the expression of CRF mRNA.

More recently, we have explored whether an analogous albeit opposite form of neuroplasticity may take place in CRF-releasing neurones following a reverse manipulation i.e. exposure to adverse early-life experiences. Converging evidence from various laboratories has indicated a lack of consistent effects upon HPA programming by maternal separation protocols in mice. Thus, we adopted a model of fragmented maternal care that produces enduring neuroendocrine and behavioural abnormalities. This experimental paradigm is based on a reduction of the nesting material (2/3) and the introduction of a fine gauge steel grid to house the dam and pups in order to prevent stable nest formation. Such an environment induces alterations in the maternal behaviour of the dam (i.e. shortened bout of nurturing behaviour and frequent shifts between behaviours) and recapitulates an important element of neglect in humans where the mother is present, yet the quality of care is impaired. We have utilised a combined electrophysiological and immunohistochemical approach to investigate possible alterations in the inhibitory–excitatory balance impinging upon CRF-releasing neurones as a consequence of chronic ELS exposure in neonatal mice (P18-P26). Consistent with the working hypothesis, ELS induced a significant increase in the number and function of glutamatergic synapses apposing CRF-releasing neurones, whereas only modest plasticity was associated with the GABAergic inputs to these neurones. Most prominently, a concomitant dramatic increase in the tonic glutamatergic conductance of CRF-releasing neurones was apparent for ELS-exposed mice and this up-regulation appeared to originate from impaired astrocytic function of the glutamate transporter ( – Fig. 3). Interestingly, the ELS-induced increase of the excitatory drive onto CRF neurones blunted inhibition of action potential firing in these neurones by physiologically relevant concentrations of 5α3α-THPROG (Fig. 3). This observation suggests that in response to a stressful challenge, the inhibitory actions of the stress-induced levels of neurosteroids may be compromised during adolescence and possibly in adulthood as a consequence of the plasticity induced by the negative early-life experience. Although, only modest changes in GABAAR-mediated inhibition could be detected, a more detailed investigation is required to determine whether ELS exposure induces alterations in the expression of specific GABAAR isoforms or indeed the subcellular localisation of GABAergic inputs to mpd neurones (e.g. see ).

Intriguingly, we have found that mice lacking the δ subunit of the GABAAR (δ0/0 mice) share with ELS mice similar PVN glutamatergic plasticity,namely an increased synaptic and extrasynaptic glutamatergic drive and a blunted neurosteroid action upon the neuronal discharge of CRF-releasing neurones. These findings may appear paradoxical, as extrasynaptic δ-containing GABAARs, a putatively highly sensitive neurosteroid target are not expressed within the PVN ( although see ). However, a plausible explanation is offered by the observation that δ0/0 pups exhibit phenotypic features of abnormal maternal care, and in agreement, in common with ELS mice, display a significant and long lasting up-regulation of CRF expression within the PVN Furthermore, exposure to early-life adversity dramatically exacerbates the δ0/0 phenotype with greatly increased perinatal and adult mortality. A reduced maternal care for δ0/0 pups may not be altogether unexpected given that an increased dopamine release from the ventral tegmental area (VTA) to the nucleus accumbens shell in the dam is associated with the onset, duration and magnitude of licking-grooming bouts, an important component of maternal care in rodents, and presynaptic δ-GABAARs may regulate the dopaminergic output of VTA neurones. Further, intriguingly, a mouse model of chronic stress exhibits a long-lasting significant decrease in δ-GABAAR expression in the VTA. Nevertheless, additional studies, such as cross-fostering, are required to establish the relative contribution genetic and environmental factors make to the described δ0/0 phenotype. In this regard, the reported association of SNPs in the GABRD gene with childhood-onset mood disorders raises the prospect that specific GABAAR genetic abnormalities may underlie susceptibility to stressful experiences and thus contribute to the development of psychopathology in humans.

Given the pivotal role of NRSF in the regulation of CRF gene expression in the mouse model of augmented maternal care described by, the contribution of NRSF, or indeed other transcription repressors, to the PVN plasticity in offspring of models of impaired maternal cares (e.g. of ELS and δ0/0) deserve a detailed investigation. Nevertheless, the evidence described is consistent with the notion that alterations in excitatory glutamatergic transmission coupled with blunted neurosteroid actions early in postnatal development may be an important molecular signal to initiate programming of the stress axis. Further, from a clinical perspective, abnormal regulation of glutamatergic transmission in animal models of chronic stress appear relevant and consistent with recent therapeutic strategies targeting inhibition of ionotropic glutamate receptors, e.g. NMDA receptors for the treatment of stress-related psychiatric disturbances e.g. depression.

Neuroplasticity of extra-hypothalamic stress centres

As described in Section 3.1, the hypothalamic PVN sub-serves the combined role of integrating multiple inputs from hypothalamic and extra-hypothalamic stress-responsive regions and initiating the stress response. However, multiple forebrain and limbic structures, including the hippocampus, amygdala and mPFC appear to operate in a parallel fashion to process and integrate psychogenic and systemic stimuli to coordinate HPA axis activity appropriately. The network activity of these limbic regions is determined in a large part by the activity of inhibitory GABAergic interneurons, and as such, dysfunction in GABAergic transmission within these brain regions may be predicted to impart susceptibility to stressor exposure and to the development of psychiatric disorders. Indeed, there is substantial preclinical and clinical evidence indicating that alterations in GABAergic inhibition may be a contributing factor in the pathogenesis of affective disorders such as depression (see section below; ). As noted above, we have found in mice that exposure to fragmented maternal care early in life results in limited apparent plasticity in the GABAergic inputs to PVN mpd neurones (although see below). However, there is substantial evidence that early-life experiences causes alterations in GABAAR-mediated signalling in other stress-sensitive brain regions. The following sections will discuss the influence of early-life experience upon the maturation of GABAergic circuits within these limbic and forebrain regions, highlighting the potential role for neurosteroids within this process and the implications that plasticity in these brain structures may have upon the actions of these endogenous modulators upon GABAergic transmission.

The quality of early-life experience has been associated with alterations in GABAAR subunit expression in a number of brain regions within the stress neurocircuitry. Moreover, such plasticity appears concomitant to perturbations in behavioural and neuroendocrine responses to stressor exposure in adulthood. Alterations in GABAAR expression in regions of the amygdala, NTS and locus coeruleus (LC) were inferred from autoradiography binding studies using [3H] flunitrazepam, where animals exposed to postnatal handling (P1–P14) displayed an increase in central BDZ binding compared to non-handled and maternally separated rats. This increase in central BDZ binding in handled animals was accompanied by an increase in γ2 mRNA in these brain regions and reduced fearfulness in response to novelty. Comparable perturbations, namely a significant reduction in the expression of the α1 subunit but up-regulation of α2 subunit levels, have been described for DGGCs of rat pups exposed to two periods of handling with maternal separation (HMS) on P9 (30 min) and P10 (360 min; ). In general, adult offspring that received a high level of maternal care (i.e. high LG-ABN) displayed significantly greater mRNA encoding α1 and β3 subunits in limbic and forebrain regions when compared to those that received low levels of maternal care. Intriguingly, alterations in GABAAR subunit expression associated with variations in maternal care are most pronounced in regions of the amygdaloid complex, an important brain region for the processing of “psychogenic” stressors and a key area implicated in the development of fear learning. Specifically, the central (CeA), basolateral (BLA) and lateral (LA) amygdaloid nuclei of adult offspring that experienced high-levels of maternal care, displayed significantly greater mRNA expression levels of both γ1 and γ2 subunits, the latter being important in mediating the majority of actions by benzodiazepines. Conversely, the mRNA levels of α3 and the BZ-insensitive α4 subunit increased in the CeA and BLA of mice exposed to low quality maternal care. Such changes will impact upon the functional and pharmacological properties of GABAA receptors, including, potentially their sensitivity to neurosteroids. However, as noted above (Sections 1 and 2) in addition to the receptor subunit composition, the effects of neurosteroids are potentially, influenced by other mechanisms such as local steroid metabolism and phosphorylation state of the receptor or associated proteins. Thus, elucidating possible alterations in these regulatory processes e.g. altered expression of steroidoigenic enzymes, may warrant future detailed investigations. A precedent in this respect is offered by the demonstrated alteration in the activity of steroidogenic enzymes e.g. 5α-reductase in forebrain regions in a socially isolated mouse model of chronic stress.

The amygdala has been identified as a key structure in mediating the anxiolytic and the antidepressant effects of 5α3α-THPROG. Therefore, for this brain region understanding the impact of such alterations in GABAAR gene expression on synaptic and extrasynaptic inhibitory signalling may be particularly pertinent.

The ELS–induced alterations in GABAAR expression in the extra-hypothalamic regions described above are likely to occur in conjunction with alterations in excitatory glutamatergic transmission. Similarly to the GABAergic system, relatively little is known regarding the specific functional alterations in glutamatergic transmission at the synaptic level (i.e. properties of EPSCs) within limbic and forebrain structures following early life stress. However, perturbations in glutamatergic transmission have been inferred from morphological and functional studies, primarily in the hippocampus. For example, in rats, exposure to fragmented early-life stress (as described for mice in Section 5.1) results in significant cognitive deficits in adulthood, which are associated with impaired hippocampal LTP, dendritic atrophy and a reduction in spine numbers ( reviewed in ). Furthermore, in rats, offspring exposed to low levels of maternal care exhibited enhanced basal NMDAR function (measured by an increase in NMDA/AMPA evoked EPSCs ratio) in the DG, which was associated with increased NR1, NR2A and NR2B expression ( reviewed in ). Collectively these observations indicate alterations in glutamatergic transmission in stress-related brain regions are likely to accompany stress-induced plasticity in the GABAergic system during development. Elucidating the specific functional changes in excitatory/inhibitory balance both at the synaptic and extrasynaptic levels and establishing how plasticity in the GABAergic and glutamatergic systems may interact to influence network activity, and hence output from these extra-hypothalamic brain areas, should offer an important focused scope for future studies.

Dysfunction of the GABAergic system

Exposure to early-life stress has consistently been shown to induce significant plasticity in the functional and morphological properties of principal cells in limbic and forebrain regions, However, the changes in the expression of GABAAR subunits in limbic and forebrain regions induced by early-life experience may also be accompanied by alterations in the number and/or localisation of GABAergic interneurons including those surrounding the PVN region. Such adaptations may have a significant impact upon the development of an organism’s ability to process and cope with stressor exposure. Indeed, GABAergic interneurons represent a highly diverse class of inhibitory neurones that interact with glutamatergic principal cells in a domain-specific manner, supporting the temporal dynamics of synaptic transmission and network oscillations, both of which are essential for implementing specific brain states. Alterations to interneurone function albeit with some differences dependent on the species investigated and the protocol employed, have been inferred from immunohistochemical studies measuring the levels of calcium binding proteins [CBPs e.g. parvalbumin (PV), calretinin, calbindin] expressed primarily in GABAergic interneurons. Thus, a number of rodent brain regions including the prelimbic prefrontal cortex (plPFC), anterior cingulate cortex (ACd), precentral medial cortex (PrCm; ) and the dentate gyrus exhibit reduced levels of CBPs following various manipulations of maternal care. Although these studies do not provide direct functional evidence supporting ELS-induced alterations in GABAergic transmission, they do suggest potential plasticity of inhibitory interneurons following ELS, as the reduced PV expression is indicative either of a decrease in interneuron numbers, and/or alterations in interneuron activity. A precedent in this regard is offered by the documented association between abnormal cortical levels of PV and GABAergic dysfunction both in animal models of schizophrenia and schizophrenic patients. Furthermore, clinical studies also highlight a loss of GABAergic interneurons in patients suffering from stress-related psychopatholgy e.g., depression and a loss of GABAergic signals is apparent in imaging studies.

Different types of inhibitory interneurons synapse onto distinct subcellular regions of principle cells (e.g. axon initial segment, dendrites, cell soma), thereby imparting distinct spatiotemporal GABAergic conductances onto the pyramidal cell, the pattern of which changes during particular physiological and pathophysiological states. Both in the hippocampus and cortex, current evidence supports a selective targeting of interneuron subtype to principal neurones cellular domains associated with the expression of a distinct GABAAR subunit complement. Thus, experience-induced alterations in dendritic/axonal morphology, associated changes to the subcellular localisation of GABAergic interneuron synapses onto principle cells, or functional plasticity in the GABAARs expressed at these distinct synapses, may significantly influence the neuronal and behavioural response to stress in adulthood. In support of such a notion, the propagation of locally evoked activity in the DG relative to that evoked the in CA1 was reduced in a rodent model (chronic mild stress [CMS]) of depression. Importantly such a reduction in activity propagation in the DG relative to the CA1 was associated with the behavioural phenotype of CMS-exposed animals in the forced swim (FST) and open field tests (OFT). These findings are consistent with the proposal that alterations in network dynamics may underlie behavioural changes accompanying chronic stress.

Stress-associated plasticity: a role for neurosteroids?

The early postnatal period, which is characterised by the stress-hyporesponsive period (SHRP, P2–P14 – Fig. 4), represents a time of considerable plasticity within the CNS with ongoing neuronal migration, synaptogenesis and apoptosis. Interestingly, in rodents the cortical levels of the endogenous neurosteroid, 5α3α-THPROG vary considerably during postnatal development, falling precipitously prior to parturition and remaining relatively lower for the first week of life ( – Fig. 4). However, during the second postnatal week, a transient increase in the levels of 5α3α-THPROG between P10–P14 is observed, which return to low adult levels on P15 ( – Fig. 4). This dynamic regulation of neurosteroid levels during early developmental stages raises the prospect of a likely physiological role for neurosteroids in cortical maturation. Consistent with such a notion, perturbations in the levels of endogenous neurosteroids, such as 5α3α-THPROG during early postnatal development have a significant impact upon the localisation of PV-expressing GABAergic interneurons of the PFC in adulthood. Specifically, the ratio of PV-expressing neurones in the deep (layers V–VI) vs superficial (layers I–III) layers of adult PFC is increased two fold in rats following neonatal (P1 or P5) administration of 5α3α-THPROG (10 mg/kg – ). An enhancement of GABAAR function by the neurosteroid appears to be the likely mechanism underlying the observed anatomical rearrangement as similar changes in interneuron placement become apparent following postnatal exposure to the benzodiazepine, flunitrazepam. Such an effect of 5α3α-THPROG upon interneuron localisation is consistent with the observation that ambient GABA promotes cortical entry of tangentially migrating neurons derived from the medial ganglionic eminence (MGE). Similarly, a BZ (diazepam)-mediated enhancement of GABAAR function increased the migration of MGE neurones. Interestingly, prenatal exposure to ethanol also promotes premature tangential migration of GABAergic interneurons (a proportion of which originate in the MGE) by increasing the ambient levels of GABA and enhancing the sensitivity of migrating interneurons to this neurotransmitter. Given the documented effects of both BZs and ethanol upon hippocampal neurosteroidgeneis (; see Section 2.2), it is tempting to speculate that at least some of these effects may be indeed mediated by endogenous neurosteroids. Nevertheless it should be noted that dynamic alterations in GABAAR subunit expression have also been implicated in the process of interneuron migration and thus, may provide an additional potential direct or indirect e.g. via neurosteroids mechanism for the enhanced GABA sensitivity following ethanol exposure. Moreover, intriguingly, the secondary early postnatal neurosteroid peak at P10 in cortex coincides with the switch in the polarity of GABA actions from depolarising to hyperpolarising (due to the increased expression of the potassium-chloride co-transporter, KCC2 and subsequent reduction in intracellular Cl-concentration – Fig. 4) suggesting a possible mechanistic link between the two phenomena.

A much improved understanding of the impact of early life adversity upon the integration and localisation of interneurons into principle cell networks and the timing of the switch in the polarity of the GABA response offers ample and immediate scope for future investigations. As disruption of maternal care alters hippocampal neurosteroid levels, it is reasonable to predict that changes in neurosteroidogenesis may occur in a number of brain regions and thus, may be a more widespread important mechanism contributing to early-life stress-induced neuronal plasticity than is currently appreciated.

Neurosteroid action, GABAARs and stress: implications for stress-related psychopathology

It is widely accepted that stress represents a significant risk factor for the development of psychiatric disturbances e.g. depression. Despite the prevalence of major depressive disorders as a leading cause of disability worldwide, the neurobiological processes that underlie the emotional, cognitive and neuroendocrine perturbations associated with these multifactorial disorders remains relatively poorly understood, hindering the development of novel therapeutics. Specifically, the most commonly prescribed antidepressants, the selective serotonin reuptake inhibitors (e.g. fluoxetine) have a relatively long latency for therapeutic benefit (2–3 weeks) and are only moderately effective, with more than one third of depressed patients remaining treatment-resistant. Over recent years significant efforts to identify novel pathogenic and therapeutically relevant mechanisms for major depressive disorders have gathered convincing evidence from both preclinical and clinical studies implicating both GABAergic and glutamatergic systems. Such findings are consistent with (i) a prominent role played by the excitatory-inhibitory balance in the regulation of the stress response, and (ii) the documented association between chronic stress exposure with consequent dysfunctional regulation of the stress response and the subsequent development of psychopathology. The following section will review this field of research with a specific emphasis on the putative pathological and potentially therapeutically relevant roles of GABA and neurosteroids to alter the inhibitory-excitatory balance. A detailed review of the glutamatergic hypothesis of depression is beyond the scope of this review and can be found elsewhere (see ).

GABA, neurosteroids and depressive disorders

Findings form clinical and preclinical studies have provided compelling evidence for an association between alterations in GABAergic transmission and stress-related psychiatric disorders including depression. Abnormal GABA signalling in major depressive disorders was initially suggested following studies from the early 1980s that demonstrated reduced plasma and cerebrospinal fluid (CSF) levels of GABA in patients suffering from depressive disorders, an observation subsequently confirmed by magnetic resonance spectroscopy studies of GABA levels. Moreover, a reduction in the density of GABAergic interneurons has been reported in the cortex and amygdala of depressed patients. Post-mortem microarray studies have additionally indicated widespread alterations in the expression of GABAAR subunits and/or GABAAR-associated binding proteins specifically in suicide victims suffering from major depressive disorders, thus reinforcing the notion of a pathologically relevant association between GABAergic deficits and depression.

Although there are considerable limitations in interpreting behavioural data from rodent models of psychiatric disorders, evidence emerging from such studies is nevertheless consistent with a deficit in GABAergic inhibition in the pathogenesis of depressive-like behaviours. For example, heterozygous deletion of the γ2 GABAAR (γ2+/−) subunit results in a brain region-specific reduction (6–35%) in [3H] flumazenil binding and receptor clustering, with the most pronounced changes occurring in limbic and cortical regions. Importantly, this deficit in GABAAR function associates with increased behavioural responses to aversive stimuli such as novelty, exposed space and brightly illuminated areas, all indicative of an anxious-like phenotype. Recent studies have revealed that selectively inducing the heterozygous γ2 subunit deletion in developing forebrain glutamatergic neurones not only recapitulates the behavioural deficits associated with the global γ2+/−, but also results in an increased basal HPA axis activity. Although currently not known, it is tempting to speculate that neurosteroids, the levels of which are normally elevated during early development (Fig. 4) may be implicated in the development of these perturbations. The observation that the development of a hyperactive HPA axis during the neonatal period associates with an anxious and depressive adult phenotype when a genetically-engineered γ2-GABAAR deficit is introduced embryonically, but not in the fourth postnatal week, is intriguing in this regard. Interestingly, however, pharmacological manipulation of GABAAR function at specific developmental time points with the BDZ, diazepam, associated with the development of distinct behavioural phenotypes in adulthood. Thus, diazepam administration at P10–P16 (but not during subsequent weeks) resulted in increased anxiety-like behaviour on the elevated plus maze (EPM) in adulthood, while the same treatment selectively between P29-35 resulted in an increased immobility i.e. a possible surrogate of depressive-like behaviour in the FST in adulthood. These observations suggest that the generation of anxiety- and depressive-like behaviours as measured in the EPM and FS tests respectively, are highly sensitive to manipulation of GABAergic inhibition mediated by γ2-GABAARs during distinct critical periods of postnatal development. Whether neurosteroids contribute to these phenotypes is not known but warrants further investigation, particularly in the light of the role of neurosteroidogenesis in the midazolam mediated effects in hippocampal function and the documented agonist activity of diazepam at the TSPO receptor.

Support for 3α-reduced neurosteroids in the pathogenesis of depressive disorders has derived from preclinical and clinical studies of the past two decades, which postulated a therapeutically relevant contribution by these endogenous modulators to the anxiolytic properties of some SSRIs (e.g. fluoxetine –. Thus, the plasma and CSF levels of 5α3α-THPROG are reduced in depressed patients and, similarly in animal models of depression, or post-traumatic stress disorder (PTSD) in a brain region specific manner. Furthermore, exogenous neurosteroid treatment produces antidepressant-like effects in a rodent model of chronic social isolation. Of note and potential clinical relevance, the levels of 3β-reduced neurosteroids e.g. isopregnanolone (3β-THPROG), which at relatively high concentrations is a negative modulator of GABAAR function, appeared increased in chronic fatigue syndrome, a condition sharing features with depression. Similarly, a chemically-induced panic attack was associated with a pronounced increase in the levels of isopregnanolone in panic disorder patients, who in absence of panic attacks display decreased levels of the same neurosteroid relative to a cohort of healthy controls. Thus, collectively, these findings suggest a potential contribution of this steroid to the symptomatology of psychiatric disorders. Interestingly, studies in rodents have additionally demonstrated that the brain levels of 5α3α-THPROG are normalised following acute treatment with the SSRI, fluoxetine, in a stereoselective manner. These findings have a human correlate as CSF levels of this neurosteroid are restored in depressed patients following SSRI treatment in a manner which correlates with improved symptomatology. Crucially, fluoxetine increased the levels of neurosteroids independently of any effect upon serotonin reuptake and on a rapid time scale (i.e. ∼30 min) that is not compatible with that associated with the clinical improvements reported for SSRI treatment (i.e. ∼3 weeks; ). Such findings have thus raised the suggestion that an enhancement of GABAAR-mediated inhibition may contribute to the anxiolytic actions of these antidepressants. The mechanism by which fluoxetine and other SSRIs (e.g. paroxetine) increase the levels of 5α3α-THPROG was initially postulated to involve modulation of 3α-HSD activity. However, a direct interaction between SSRIs and 3α-HSD remains controversial as subsequent studies failed to support the initial findings.

Establishing with confidence whether the increase in neurosteroid levels associated with SSRI treatment contributes to the therapeutic action of these antidepressants in humans has proved difficult to assess and remains unclear. Indeed, although various SSRIs (e.g. fluoxetine, paroxetine) elevate neurosteroid levels and alleviate depressive symptoms, a number of other pharmacological and non-pharmacological antidepressant treatments produce clinical improvements in patients suffering from major depressive disorders, independently of any effect upon the levels of 5α3α-THPROG. Challenging the clinical significance of increased neurosteroid levels ameliorating depression, 5α3α-THPROG levels increased in both responders and non-responders, following treatment with the antidepressant mirtazapine. Thus, it remains unclear whether the normalisation of 5α3α-THPROG levels following fluoxetine treatment is actively involved in alleviating depressive symptoms, or is simply a pharmacological by-product associated with clinical benefit. Nevertheless, the recent observation that the 18 kDa-translocator protein (TSPO) is the target of novel anxiolytic drugs (e.g. XBD173), that stimulate neurosteroidogenesis to produce anxiolytic effects, without the side-effect profile typically associated with classical BDZs (e.g. sedation, tolerance), suggests that neurosteroids and/or neurosteroidogenic compounds may still offer a promising approach for the treatment of affective disorders.

Hippocampal neurogenesis and stress: a role for GABA AR and neurosteroids and relevance to stress-associated psychopathology and treatment

Over recent years a relatively novel, but increasingly prevalent avenue of research aimed at understanding the pathophysiology of cognitive and major depressive disorders has focused upon the mechanisms regulating adult hippocampal neurogenesis. Adult neurogenesis is a complex multistep process that occurs in the mammalian hippocampus, striatum and olfactory bulb, and appears, in animal models, to be particularly sensitive to physiological and environmental conditions, including acute or chronic stressor exposure.

In this context, the role of GABAAR-mediated signalling in the proliferation, integration and survival of newborn hippocampal neurones may be of particular significance. In common with neonates, newborn neurones in the adult hippocampus undergo a stereotypical integration process, where they initially receive tonic GABAAR activation followed by the generation of GABAAR-mediated synaptic inputs and finally glutamate-mediated synaptic inputs. Furthermore, electrophysiological analysis has revealed that GABA depolarises immature neural progenitor cells for the first two–three weeks of their neuronal development, an action that is crucial for normal structural and functional maturation as well as network integration. The GABAergic effects on cell proliferation, initial migration and early dendritic arborisation are mediated at least in the hippocampus by α4-containing GABAARs, whilst α2-GABAARs regulate the position of newborn neurones within the DG and the late maturation of their dendritic processes. Stress in adult rodent models can induce suppression of neurogenesis, which is reversible following the cessation of stressor exposure or pharmacological treatment. However, early-life stress-induced inhibition of neurogenesis appears to persist throughout life. Thus, various models of prenatal stress exhibit cognitive and emotional deficits that associate with a long lasting impairment of hippocampal neurogenesis. Although postnatal stress produces more variable results, in general similar deficits in hippocampal neurogenesis appear to prevail. Importantly, the effect of early life environment upon adult neurogenesis and the responsivity to novel experiences in adulthood appear to be dependent upon a number of factors including the age at which neurogenesis is determined, the frequency of the postnatal stressor (i.e. being either single or recurrent) and the gender (reviewed in ). For example, exposure to a recurrent maternal separation paradigm during postnatal development impaired stress-induced plasticity of hippocampal neurogenesis in adulthood, whilst exposure to a single prolonged postnatal (P3) stress resulted in a suppression of adult hippocampal neurogenesis, impaired spatial learning, yet an enhancement of contextual learning in a stressful environment. Interestingly, evidence from animal and clinical studies lends considerable correlative support to the notion that new neurones are required in the adult brain for antidepressant efficacy, but their role in the pathogenesis of mood disorders remains to be fully elucidated. Specifically, the chronic treatment of rodents with several classes of antidepressants has resulted in an increase in hippocampal neurogenesis on a time scale consistent with the clinical efficacy of antidepressant treatment in humans. In non-human primates stress also decreased neurogenesis, an effect prevented by the concomitant administration of the antidepressant tianeptine. In further support, ablation of hippocampal neurogenesis using genetic and radiological methods attenuated the neurogenic and behavioural effects of antidepressant treatment. However, it should be noted that the therapeutic actions of certain antidepressant compounds have been reported to occur in a neurogenesis-independent manner. Moreover, there is a general consensus that ablation of hippocampal neurogenesis is not sufficient to induce a depressive or anxiety-like behaviour in rodents (reviewed in ). Thus, despite evidence suggesting a role for new born hippocampal neurones in mediating the efficacy of certain antidepressant compounds, a clear and coherent model explaining the mechanisms whereby adult born neurones contribute to emotional behaviours and/ or to the pathogenesis of depressive disorders remains to be formulated. Specifically, further studies are required to elucidate the relationship between the role of new-born hippocampal neurones in the regulation of emotional behaviours and to determine how stress-induced changes in neurogenesis are relevant to the pathogenesis of depressive disorders.

Nevertheless, because GABA-mediated signalling is an important component of adult neurogenesis through a process that appears largely to recapitulate the neuronal developmental processes of embryonic/ neonatal stages, the GABA-modulatory actions of neurosteroids may be relevant and of possible therapeutic interest. Consistent with this suggestion, 5α3α-THPROG does exhibit proliferative effects in rat hippocampal, and human cortical progenitor cells in culture, raising the prospect that the regenerative properties of these endogenous neuromodulators may be of therapeutic benefit. Support for this proposal is provided by the effects of 5α3α-THPROG upon hippocampal neurogenesis and cognitive function in a mouse model of Alzheimer’s disease (3xTgAD). Thus, treatment of 3xTgAD mice with 5α3α-THPROG dose-dependently normalised abnormal cell proliferation in the SGZ to levels found in wild type mice and reversed the hippocampal dependent cognitive deficits. Importantly, the 5α3α-THPROG-induced survival of neural progenitors in the 3xTgAD mice correlated strongly with improved memory performance in these mice, suggesting that early deficits in neurogenesis may indeed contribute to the cognitive decline associated with Alzheimer’s disease. A similar beneficial effect of neurosteroid treatment upon hippocampal neurogenesis can therefore be postulated in stress-related pathologies. In agreement, in a social isolation rodent model of chronic stress, 5α3α-THPROG treatment either concomitantly, or following the period of social isolation, prevented the development of depressive-like behaviours measured by the novelty supressed feeding (NSF) and the forced swim test (FST) and concomitantly normalised the stress-induced suppression of hippocampal neurogenesis. Importantly, the antidepressant effects of 5α3α-THPROG in the FST and NSF paradigms were additionally accompanied by a normalisation of stress-induced BDNF deficits in the hippocampus. Although a clear mechanistic link remains to be established, evidence for a positive correlative association between 5α3α-THPROG levels and BDNF mRNA expression have been reported in a number of stress-related brain regions including the hippocampus, PFC and amygdala. The increase in BDNF following neurosteroid treatment is intriguing in the contest of the recently reported treatment of resistant-type of depression with ketamine. Specifically, ketamine has been suggested to produce antidepressant effects by increasing synaptogenesis through complex intracellular signalling cascades, which appear dependent upon the increased synthesis and release of BDNF. Thus, establishing the relationship between BDNF and level of neurosteroids such as 5α3α-THPROG, and the potential effects of neurosteroids upon synaptogenesis in limbic and forebrain regions warrants further studies.

Concluding remarks

Since the pioneering discovery by Purdy and colleagues that a mild acute stress induced the de novo synthesis of GABAAR-active neurosteroids in the rodent brain, converging evidence from the past two decades has deduced an important role for these modulators of neuronal excitability in the regulation and programming of the stress response. However, our understanding of the specific mechanisms whereby neurosteroids may act to regulate both the programming of the stress response and some of the adaptations that ensue after acute as well chronic stress challenges in adulthood requires much refinement.

Firstly, our knowledge of the molecular signals that mastermind the expression of the genes for the synthesis and degradation of neurosteroids both in health and disease is limited. Furthermore, the recent report documenting a female-selective association between SNPs in the aldo–keto reductase 1 (AKRC1) and anxiety levels highlights the potential importance of gender, further emphasising the importance of focused investigations in this area.

Secondly, although GABAARs are established as selective molecular targets of the stress-induced pregnane neurosteroids such as 5α,3α-THPROG and 5α,3α-THDOC, in contrast to other GABAAR modulators e.g. benzodiazepines, a detailed understanding of the specific receptor subtypes mediating the constellation of neurosteroid behaviours is not known. However, the identification of the molecular determinants for neurosteroid binding at the GABAAR and the recent development of mice engineered to express neurosteroid-insensitive GABAAR isoforms should be informative in this regard. A similar approach should uncover the role specific receptor isoforms play in mediating the action of neurosteroids, both during early programming of the stress response and in the regulation of neuronal and behavioural adaptations to acute and/or chronic stress challenges.

Lastly, epidemiological studies suggest stress-associated psychopathology to exhibit sex-bias and, for example, women are ∼2–3 times more likely to be affected by mood disorders during their reproductive years. Indirect evidence, as discussed above (Section 2.2 and 7: ), suggest a potential role of neurosteroids in the gender-selectivity of stress-related psychopathology. Future efforts in the preclinical arena should therefore be conducted in both female and male subjects. Although appreciating the caveats associated with work in animals, such studies are nevertheless likely to prove invaluable in identifying candidate mechanisms and genes on which future human clinical research should focus.

References 311

  1. 1.

    Agis-Balboa R.C., Pinna G., Zhubi A., Maloku E., Veldic M., Costa E., Guidotti A. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc. Natl. Acad. Sci. USA. 2006;103:14602-14607.

    Not in our library10.1073/pnas.0606544103

  2. 2.

    Airan R.D., Meltzer L.A., Roy M., Gong Y., Chen H., Deisseroth K. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science. 2007;317:819-823.

    Not in our library10.1126/science.1144400

  3. 3.

    Akk G., Shu H.J., Wang C., Steinbach J.H., Zorumski C.F., Covey D.F., Mennerick S. Neurosteroid access to the GABAA receptor. J. Neurosci.: Off. J. Soc. Neurosci. 2005;25:11605-11613.

    Not in our library10.1523/jneurosci.4173-05.2005

  4. 4.

    Akk G., Covey D.F., Evers A.S., Steinbach J.H., Zorumski C.F., Mennerick S. Mechanisms of neurosteroid interactions with GABAA receptors. Pharmacol Ther. 2007;116:35-57.

    Not in our library10.1016/j.pharmthera.2007.03.004

  5. 5.

    Akk G., Li P., Bracamontes J., Reichert D.E., Covey D.F., Steinbach J.H. Mutations of the GABA-A receptor alpha1 subunit M1 domain reveal unexpected complexity for modulation by neuroactive steroids. Mol. Pharmacol. 2008;74:614-627.

    Not in our library10.1124/mol.108.048520

  6. 6.

    Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav. Brain Res. 1999;106:119-125.

    Not in our library10.1016/s0166-4328(99)00101-1

  7. 7.

    Anholt R.R., Murphy K.M., Mack G.E., Snyder S.H. Peripheral-type benzodiazepine receptors in the central nervous system: localization to olfactory nerves. J. Neurosci.: Off. J. Soc. Neurosci. 1984;4:593-603.

    Not in our library10.1523/jneurosci.04-02-00593.1984

  8. 8.

    Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., Kavalali E.T., Monteggia L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91-95.

    Not in our library10.1038/nature10130

  9. 9.

    Avishai-Eliner S., Eghbal-Ahmadi M., Tabachnik E., Brunson K.L., Baram T.Z. Down-regulation of hypothalamic corticotropin-releasing hormone messenger ribonucleic acid (mRNA) precedes early-life experience-induced changes in hippocampal glucocorticoid receptor mRNA. Endocrinology. 2001;142:89-97.

    Not in our library10.1210/endo.142.1.7917

  10. 10.

    Baghai T.C., di Michele F., Schule C., Eser D., Zwanzger P., Pasini A., Romeo E., Rupprecht R. Plasma concentrations of neuroactive steroids before and after electroconvulsive therapy in major depression. Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol. 2005;30:1181-1186.

    Not in our library10.1038/sj.npp.1300684

  11. 11.

    Bagot R.C., Tse Y.C., Nguyen H.B., Wong A.S., Meaney M.J., Wong T.P. Maternal care influences hippocampal N-methyl-d-aspartate receptor function and dynamic regulation by corticosterone in adulthood. Biol. Psychiatry. 2012;72:491-498.

    Not in our library10.1016/j.biopsych.2012.03.016

  12. 12.

    Bale T.L., Baram T.Z., Brown A.S., Goldstein J.M., Insel T.R., McCarthy M.M., Nemeroff C.B., Reyes T.M., Simerly R.B., Susser E.S., Nestler E.J. Early life programming and neurodevelopmental disorders. Biol. Psychiatry. 2010;68:314-319.

    Not in our library10.1016/j.biopsych.2010.05.028

  13. 13.

    Bali B., Erdelyi F., Szabo G., Kovacs K.J. Visualization of stress-responsive inhibitory circuits in the GAD65-eGFP transgenic mice. Neurosci. Lett. 2005;380:60-65.

    Not in our library10.1016/j.neulet.2005.01.014

  14. 14.

    Baram T.Z., Davis E.P., Obenaus A., Sandman C.A., Small S.L., Solodkin A., Stern H. Fragmentation and unpredictability of early-life experience in mental disorders. Am. J. Psychiatry. 2012;169:907-915.

    Not in our library10.1176/appi.ajp.2012.11091347

  15. 15.

    Barbaccia M.L. Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs. Crit. Rev. Neurobiol. 2004;16:67-74.

    Not in our library10.1615/critrevneurobiol.v16.i12.70

  16. 16.

    Barbaccia M.L., Roscetti G., Trabucchi M., Cuccheddu T., Concas A., Biggio G. Neurosteroids in the brain of handling-habituated and naive rats: effect of CO2 inhalation. Eur. J. Pharmacol. 1994;261:317-320.

    Not in our library10.1016/0014-2999(94)90123-6

  17. 17.

    Barbaccia M.L., Roscetti G., Trabucchi M., Mostallino M.C., Concas A., Purdy R.H., Biggio G. Time-dependent changes in rat brain neuroactive steroid concentrations and GABAA receptor function after acute stress. Neuroendocrinology. 1996;63:166-172.

    Not in our library10.1159/000126953

  18. 18.

    Barbaccia M.L., Serra M., Purdy R.H., Biggio G. Stress and neuroactive steroids. Int. Rev. Neurobiol. 2001;46:243-272.

    Not in our library10.1016/s0074-7742(01)46065-x

  19. 19.

    Baulieu E.E., Fuxe K., Gustafsson J.A., Wetterberg L. Steroid hormones in the brain: several mechanisms? Steroid Hormone Regulation of the Brain. 1981;vol. 34:3-34.

    Not in our library

  20. 20.

    Belelli D., Herd M.B. The contraceptive agent Provera enhances GABAA receptor-mediated inhibitory neurotransmission in the rat hippocampus: evidence for endogenous neurosteroids? J. Neurosci.: Off. J. Soc. Neurosci. 2003;23:10013-10020.

    Not in our library10.1523/jneurosci.23-31-10013.2003

  21. 21.

    Belelli D., Lambert J.J. Neurosteroids: endogenous regulators of the GABAA receptor. Nat. Rev. Neurosci. 2005;6:565-575.

    Not in our library10.1038/nrn1703

  22. 22.

    Belelli D., Casula A., Ling A., Lambert J.J. The influence of subunit composition on the interaction of neurosteroids with GABAA receptors. Neuropharmacology. 2002;43:651-661.

    Not in our library10.1016/s0028-3908(02)00172-7

  23. 23.

    Belelli D., Harrison N.L., Maguire J., Macdonald R.L., Walker M.C., Cope D.W. Extrasynaptic GABAA receptors: form, pharmacology, and function. J. Neurosci.: Off. J. Soc. Neurosci. 2009;29:12757-12763.

    Not in our library10.1523/jneurosci.3340-09.2009

  24. 24.

    Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat. Rev. Neurosci. 2002;3:728-739.

    Not in our library10.1038/nrn920

  25. 25.

    Bessa J.M., Ferreira D., Melo I., Marques F., Cerqueira J.J., Palha J.A., Almeida O.F., Sousa N. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol. Psychiatry. 2009;14(764–773):739.

    Not in our library10.1038/mp.2008.119

  26. 26.

    Biggio G., Concas A., Follesa P., Sanna E., Serra M. Stress, ethanol, and neuroactive steroids. Pharmacol. Ther. 2007;116:140-171.

    Not in our library10.1016/j.pharmthera.2007.04.005

  27. 27.

    Bitran D., Hilvers R.J., Kellogg C.K. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res. 1991;561:157-161.

    Not in our library10.1016/0006-8993(91)90761-j

  28. 28.

    Bitran D., Shiekh M., McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J. Neuroendocrinol. 1995;7:171-177.

    Not in our library10.1111/j.1365-2826.1995.tb00744.x

  29. 29.

    Bitran D., Dugan M., Renda P., Ellis R., Foley M. Anxiolytic effects of the neuroactive steroid pregnanolone (3 alpha-OH-5 beta-pregnan-20-one) after microinjection in the dorsal hippocampus and lateral septum. Brain Res. 1999;850:217-224.

    Not in our library10.1016/s0006-8993(99)02150-2

  30. 30.

    Bitran D., Foley M., Audette D., Leslie N., Frye C.A. Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rat. Psychopharmacology. 2000;151:64-71.

    Not in our library10.1007/s002130000471

  31. 31.

    Bolger G.T., Mezey E., Cott J., Weissman B.A., Paul S.M., Skolnick P. Differential regulation of ‘central’ and ‘peripheral’ benzodiazepine binding sites in the rat olfactory bulb. Eur. J. Pharmacol. 1984;105:143-148.

    Not in our library10.1016/0014-2999(84)90658-7

  32. 32.

    Boudaba C., Schrader L.A., Tasker J.G. Physiological evidence for local excitatory synaptic circuits in the rat hypothalamus. J. Neurophysiol. 1997;77:3396-3400.

    Not in our library10.1152/jn.1997.77.6.3396

  33. 33.

    Boyd K.N., Kumar S., O’Buckley T.K., Porcu P., Morrow A.L. Ethanol induction of steroidogenesis in rat adrenal and brain is dependent upon pituitary ACTH release and de novo adrenal StAR synthesis. J. Neurochem. 2010;112:784-796.

    Not in our library10.1111/j.1471-4159.2009.06509.x

  34. 34.

    Brenhouse H.C., Andersen S.L. Nonsteroidal anti-inflammatory treatment prevents delayed effects of early life stress in rats. Biol. Psychiatry. 2011;70:434-440.

    Not in our library10.1016/j.biopsych.2011.05.006

  35. 35.

    Brot M.D., Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABAA receptors. Eur. J. Pharmacol. 1997;325:1-7.

    Not in our library10.1016/s0014-2999(97)00096-4

  36. 36.

    Brown N., Kerby J., Bonnert T.P., Whiting P.J., Wafford K.A. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABAA receptors. Br. J. Pharmacol. 2002;136:965-974.

    Not in our library10.1038/sj.bjp.0704795

  37. 37.

    Brummelte S., Galea L.A. Depression during pregnancy and postpartum: contribution of stress and ovarian hormones. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010;34:766-776.

    Not in our library10.1016/j.pnpbp.2009.09.006

  38. 38.

    Brunson K.L., Kramar E., Lin B., Chen Y., Colgin L.L., Yanagihara T.K., Lynch G., Baram T.Z. Mechanisms of late-onset cognitive decline after early-life stress. J. Neurosci.: Off. J. Soc. Neurosci. 2005;25:9328-9338.

    Not in our library10.1523/jneurosci.2281-05.2005

  39. 39.

    Brunton P.J., Russell J.A. Neuroendocrine control of maternal stress responses and fetal programming by stress in pregnancy. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2011;35:1178-1191.

    Not in our library10.1016/j.pnpbp.2010.12.023

  40. 40.

    Brunton P.J., Russell J.A., Hirst J.J. Allopregnanolone in the brain: protecting pregnancy and birth outcomes. Prog. Neurobiol. 2014;113:106-136.

    Not in our library10.1016/j.pneurobio.2013.08.005

  41. 41.

    Bureau M.H., Olsen R.W. GABA A receptor subtypes – ligand-binding heterogeneity Demonstrated by photoaffinity-labeling and autoradiography. J. Neurochem. 1993;61:1479-1491.

    Not in our library10.1111/j.1471-4159.1993.tb13643.x

  42. 42.
  43. 43.

    Caldji C., Francis D., Sharma S., Plotsky P.M., Meaney M.J. The effects of early rearing environment on the development of GABAA and central benzodiazepine receptor levels and novelty-induced fearfulness in the rat. Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol. 2000;22:219-229.

    Not in our library10.1016/s0893-133x(99)00110-4

  44. 44.

    Caldji C., Diorio J., Meaney M.J. Variations in maternal care alter GABAA receptor subunit expression in brain regions associated with fear. Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol. 2003;28:1950-1959.

    Not in our library10.1038/sj.npp.1300237

  45. 45.

    Callachan H., Cottrell G.A., Hather N.Y., Lambert J.J., Nooney J.M., Peters J.A. Modulation of the GABAA receptor by progesterone metabolites. Proc. Roy. Soc. Lond. B, Containing Papers Biol. Character. Royal Soc. 1987;231:359-369.

    Not in our library10.1098/rspb.1987.0049

  46. 46.

    Cameron H.A., Gould E. Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience. 1994;61:203-209.

    Not in our library10.1016/0306-4522(94)90224-0

  47. 47.

    Caraiscos V.B., Elliott E.M., You-Ten K.E., Cheng V.Y., Belelli D., Newell J.G., Jackson M.F., Lambert J.J., Rosahl T.W., Wafford K.A., MacDonald J.F., Orser B.A. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc. Natl. Acad. Sci. USA. 2004;101:3662-3667.

    Not in our library10.1073/pnas.0307231101

  48. 48.

    Carboni E., Wieland S., Lan N.C., Gee K.W. Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety. Psychopharmacology. 1996;126:173-178.

    Not in our library10.1007/bf02246353

  49. 49.

    Casellas P., Galiegue S., Basile A.S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem. Int. 2002;40:475-486.

    Not in our library10.1016/s0197-0186(01)00118-8

  50. 50.

    Castelli M.P., Casti A., Casu A., Frau R., Bortolato M., Spiga S., Ennas M.G. Regional distribution of 5alpha-reductase type 2 in the adult rat brain: an immunohistochemical analysis. Psychoneuroendocrinology. 2013;38:281-293.

    Not in our library10.1016/j.psyneuen.2012.06.008

  51. 51.

    Castren E., Hen R. Neuronal plasticity and antidepressant actions. Trends Neurosci. 2013;36:259-267.

    Not in our library10.1016/j.tins.2012.12.010

  52. 52.

    Champagne F.A., Chretien P., Stevenson C.W., Zhang T.Y., Gratton A., Meaney M.J. Variations in nucleus accumbens dopamine associated with individual differences in maternal behavior in the rat. J. Neurosci.: Off. J. Soc. Neurosci. 2004;24:4113-4123.

    Not in our library10.1523/jneurosci.5322-03.2004

  53. 53.

    Chisari M., Eisenman L.N., Covey D.F., Mennerick S., Zorumski C.F. The sticky issue of neurosteroids and GABAA receptors. Trends Neurosci. 2010;33:299-306.

    Not in our library10.1016/j.tins.2010.03.005

  54. 54.

    Cirulli F., Berry A., Alleva E. Early disruption of the mother–infant relationship: effects on brain plasticity and implications for psychopathology. Neurosci. Biobehav. Rev. 2003;27:73-82.

    Not in our library10.1016/s0149-7634(03)00010-1

  55. 55.

    Connelly W.M., Errington A.C., Crunelli V. Gamma-Hydroxybutyric acid (GHB) is not an agonist of extrasynaptic GABAA receptors. PLoS ONE. 2013;8:e79062.

    Not in our library10.1371/journal.pone.0079062

  56. 56.

    Crawley J.N., Glowa J.R., Majewska M.D., Paul S.M. Anxiolytic activity of an endogenous adrenal steroid. Brain Res. 1986;398:382-385.

    Not in our library10.1016/0006-8993(86)91500-3

  57. 57.

    Crestani F., Lorez M., Baer K., Essrich C., Benke D., Laurent J.P., Belzung C., Fritschy J.M., Luscher B., Mohler H. Decreased GABAA–receptor clustering results in enhanced anxiety and a bias for threat cues. Nat. Neurosci. 1999;2:833-839.

    Not in our library10.1038/12207

  58. 58.

    Cullinan W.E. GABAA receptor subunit expression within hypophysiotropic CRH neurons: a dual hybridization histochemical study. J. Comp. Neurol. 2000;419:344-351.

    Not in our library10.1002/(sici)1096-9861(20000410)419:3<344::aid-cne6>3.0.co;2-z

  59. 59.

    Cullinan W.E., Herman J.P., Watson S.J. Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis. J. Comp. Neurol. 1993;332:1-20.

    Not in our library10.1002/cne.903320102

  60. 60.

    Cullinan W.E., Ziegler D.R., Herman J.P. Functional role of local GABAergic influences on the HPA axis. Brain Struct. Funct. 2008;213:63-72.

    Not in our library10.1007/s00429-008-0192-2

  61. 61.

    Cuzon Carlson V.C., Yeh H.H. GABAA receptor subunit profiles of tangentially migrating neurons derived from the medial ganglionic eminence. Cereb. Cortex. 2011;21:1792-1802.

    Not in our library10.1093/cercor/bhq247

  62. 62.

    Cuzon V.C., Yeh P.W., Cheng Q., Yeh H.H. Ambient GABA promotes cortical entry of tangentially migrating cells derived from the medial ganglionic eminence. Cereb. Cortex. 2006;16:1377-1388.

    Not in our library10.1093/cercor/bhj084

  63. 63.

    Cuzon V.C., Yeh P.W., Yanagawa Y., Obata K., Yeh H.H. Ethanol consumption during early pregnancy alters the disposition of tangentially migrating GABAergic interneurons in the fetal cortex. J. Neurosci.: Off. J. Soc. Neurosci. 2008;28:1854-1864.

    Not in our library10.1523/jneurosci.5110-07.2008

  64. 64.

    Czeh B., Michaelis T., Watanabe T., Frahm J., de Biurrun G., van Kampen M., Bartolomucci A., Fuchs E. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl. Acad. Sci. USA. 2001;98:12796-12801.

    Not in our library10.1073/pnas.211427898

  65. 65.

    Czeh B., Welt T., Fischer A.K., Erhardt A., Schmitt W., Muller M.B., Toschi N., Fuchs E., Keck M.E. Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biol. Psychiatry. 2002;52:1057-1065.

    Not in our library10.1016/s0006-3223(02)01457-9

  66. 66.

    de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005;6:463-475.

    Not in our library10.1038/nrn1683

  67. 67.

    Decavel C., Van den Pol A.N. GABA: a dominant neurotransmitter in the hypothalamus. J. Comp. Neurol. 1990;302:1019-1037.

    Not in our library10.1002/cne.903020423

  68. 68.

    Decavel C., van den Pol A.N. Converging GABA- and glutamate-immunoreactive axons make synaptic contact with identified hypothalamic neurosecretory neurons. J. Comp. Neurol. 1992;316:104-116.

    Not in our library10.1002/cne.903160109

  69. 69.

    Dent G., Choi D.C., Herman J.P., Levine S. GABAergic circuits and the stress hyporesponsive period in the rat: ontogeny of glutamic acid decarboxylase (GAD) 67 mRNA expression in limbic-hypothalamic stress pathways. Brain Res. 2007;1138:1-9.

    Not in our library10.1016/j.brainres.2006.04.082

  70. 70.

    Dhir A., Rogawski M.A. Role of neurosteroids in the anticonvulsant activity of midazolam. Br. J. Pharmacol. 2012;165:2684-2691.

    Not in our library10.1111/j.1476-5381.2011.01733.x

  71. 71.

    Do Rego J.L., Seong J.Y., Burel D., Leprince J., Luu-The V., Tsutsui K., Tonon M.C., Pelletier G., Vaudry H. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front. Neuroendocrinol. 2009;30:259-301.

    Not in our library10.1016/j.yfrne.2009.05.006

  72. 72.

    Dong H.W., Swanson L.W. Projections from bed nuclei of the stria terminalis, posterior division: implications for cerebral hemisphere regulation of defensive and reproductive behaviors. J. Comp. Neurol. 2004;471:396-433.

    Not in our library10.1002/cne.20002

  73. 73.

    Dong H.W., Swanson L.W. Projections from bed nuclei of the stria terminalis, anteromedial area: cerebral hemisphere integration of neuroendocrine, autonomic, and behavioral aspects of energy balance. J. Comp. Neurol. 2006;494:142-178.

    Not in our library10.1002/cne.20788

  74. 74.

    Dong E., Matsumoto K., Uzunova V., Sugaya I., Takahata H., Nomura H., Watanabe H., Costa E., Guidotti A. Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. USA. 2001;98:2849-2854.

    Not in our library10.1073/pnas.051628598

  75. 75.

    Dong H.W., Petrovich G.D., Swanson L.W. Topography of projections from amygdala to bed nuclei of the stria terminalis. Brain Res. Brain Res. Rev. 2001;38:192-246.

    Not in our library10.1016/s0165-0173(01)00079-0

  76. 76.

    Dong H.W., Petrovich G.D., Watts A.G., Swanson L.W. Basic organization of projections from the oval and fusiform nuclei of the bed nuclei of the stria terminalis in adult rat brain. J. Comp. Neurol. 2001;436:430-455.

    Not in our library10.1002/cne.1079

  77. 77.

    Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68-72.

    Not in our library10.1126/science.1222939

  78. 78.

    Durkin, E.J., Lumb, M.J., Stanford, S.C., Moss, S.J., & Smart, S.G., 2011. Defining the role of the GABAA α2-subunit in cellular and behavioural responses to neurosteroids. 42.12 Neuroscience Meeting Planner SFN.

    Not in our library

  79. 79.

    Duveau V., Laustela S., Barth L., Gianolini F., Vogt K.E., Keist R., Chandra D., Homanics G.E., Rudolph U., Fritschy J.M. Spatiotemporal specificity of GABAA receptor-mediated regulation of adult hippocampal neurogenesis. Eur. J. Neurosci. 2011;34:362-373.

    Not in our library10.1111/j.1460-9568.2011.07782.x

  80. 80.

    Dwyer J.M., Duman R.S. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol. Psychiatry. 2013;73:1189-1198.

    Not in our library10.1016/j.biopsych.2012.11.011

  81. 81.

    Earnheart J.C., Schweizer C., Crestani F., Iwasato T., Itohara S., Mohler H., Luscher B. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J. Neurosci.: Off. J. Soc. Neurosci. 2007;27:3845-3854.

    Not in our library10.1523/jneurosci.3609-06.2007

  82. 82.

    Eechaute W.P., Dhooge W.S., Gao C.Q., Calders P., Rubens R., Weyne J., Kaufman J.M. Progesterone-transforming enzyme activity in the hypothalamus of the male rat. J. Steroid Biochem. Mol. Biol. 1999;70:159-167.

    Not in our library10.1016/s0960-0760(99)00106-5

  83. 83.

    Ehrlich I., Humeau Y., Grenier F., Ciocchi S., Herry C., Luthi A. Amygdala inhibitory circuits and the control of fear memory. Neuron. 2009;62:757-771.

    Not in our library10.1016/j.neuron.2009.05.026

  84. 84.

    Eisch A.J., Petrik D. Depression and hippocampal neurogenesis: a road to remission? Science. 2012;338:72-75.

    Not in our library10.1126/science.1222941

  85. 85.

    Engin E., Treit D. The anxiolytic-like effects of allopregnanolone vary as a function of intracerebral microinfusion site: the amygdala, medial prefrontal cortex, or hippocampus. Behav. Pharmacol. 2007;18:461-470.

    Not in our library10.1097/fbp.0b013e3282d28f6f

  86. 86.

    Eser D., di Michele F., Zwanzger P., Pasini A., Baghai T.C., Schule C., Rupprecht R., Romeo E. Panic induction with cholecystokinin-tetrapeptide (CCK-4) increases plasma concentrations of the neuroactive steroid 3α,5α tetrahydrodeoxycorticosterone (3α,5α-THDOC) in healthy volunteers. Neuropsychopharmacology. 2005;30:192-195.

    Not in our library10.1038/sj.npp.1300572

  87. 87.

    Eser D., Romeo E., Baghai T.C., di Michele F., Schule C., Pasini A., Zwanzger P., Padberg F., Rupprecht R. Neuroactive steroids as modulators of depression and anxiety. Neuroscience. 2006;138:1041-1048.

    Not in our library10.1016/j.neuroscience.2005.07.007

  88. 88.

    Evans J., Sun Y., McGregor A., Connor B. Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. Neuropharmacology. 2012;63:1315-1326.

    Not in our library10.1016/j.neuropharm.2012.08.012

  89. 89.

    Farrant M., Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat. Rev. Neurosci. 2005;6:215-229.

    Not in our library10.1038/nrn1625

  90. 90.

    Feng Y., Kapornai K., Kiss E., Tamas Z., Mayer L., Baji I., Daroczi G., Benak I., Kothencne V.O., Dombovari E., Kaczvinszk E., Besnyo M., Gadoros J., Szekely J., Kovacs M., Vetro A., Kennedy J.L., Barr C.L. Association of the GABRD gene and childhood-onset mood disorders. Genes, Brain, Behavior. 2010;9:668-672.

    Not in our library10.1111/j.1601-183x.2010.00598.x

  91. 91.

    Fenoglio K.A., Brunson K.L., Baram T.Z. Hippocampal neuroplasticity induced by early-life stress: functional and molecular aspects. Front. Neuroendocrinol. 2006;27:180-192.

    Not in our library10.1016/j.yfrne.2006.02.001

  92. 92.

    Fenoglio K.A., Chen Y., Baram T.Z. Neuroplasticity of the hypothalamic–pituitary–adrenal axis early in life requires recurrent recruitment of stress-regulating brain regions. J. Neurosci.: Off. J. Soc. Neurosci. 2006;26:2434-2442.

    Not in our library10.1523/jneurosci.4080-05.2006

  93. 93.

    Francis D.D., Meaney M.J. Maternal care and the development of stress responses. Curr. Opin. Neurobiol. 1999;9:128-134.

    Not in our library10.1016/s0959-4388(99)80016-6

  94. 94.

    Francis D., Diorio J., Liu D., Meaney M.J. Nongenomic transmission across generations of maternal behavior and stress responses in the rat. Science. 1999;286:1155-1158.

    Not in our library10.1126/science.286.5442.1155

  95. 95.

    Franklin T.B., Saab B.J., Mansuy I.M. Neural mechanisms of stress resilience and vulnerability. Neuron. 2012;75:747-761.

    Not in our library10.1016/j.neuron.2012.08.016

  96. 96.

    Fritschy J.M., Brunig I. Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol. Ther. 2003;98:299-323.

    Not in our library10.1016/s0163-7258(03)00037-8

  97. 97.

    Fritschy J.M., Mohler H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 1995;359:154-194.

    Not in our library10.1002/cne.903590111

  98. 98.

    Fritschy J.M., Panzanelli P. GABA receptors and plasticity of inhibitory neurotransmission in the central nervous system. Eur. J. Neurosci. 2014.

    Not in our library10.1111/ejn.12534

  99. 99.

    Frye C.A., Rhodes M.E., Raol Y.H., Brooks-Kayal A.R. Early postnatal stimulation alters pregnane neurosteroids in the hippocampus. Psychopharmacology. 2006;186:343-350.

    Not in our library10.1007/s00213-005-0253-7

  100. 100.

    Gao C.Q., Dhooge W.S., Kaufman J.M., Weyne J.J., Eechaute W.P. Hypothalamic 5 alpha-reductase and 3 alpha-oxidoreductase activity in the male rat. J. Steroid Biochem. Mol. Biol. 2002;80:91-98.

    Not in our library10.1016/s0960-0760(01)00168-6

  101. 101.

    Gavish M., Bachman I., Shoukrun R., Katz Y., Veenman L., Weisinger G., Weizman A. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 1999;51:629-650.

    Not in our library

  102. 102.

    Ge S., Goh E.L., Sailor K.A., Kitabatake Y., Ming G.L., Song H. GABA regulates synaptic integration of newly generated neurons in the adult brain. Nature. 2006;439:589-593.

    Not in our library10.1038/nature04404

  103. 103.

    Ge S., Pradhan D.A., Ming G.L., Song H. GABA sets the tempo for activity-dependent adult neurogenesis. Trends Neurosci. 2007;30:1-8.

    Not in our library10.1016/j.tins.2006.11.001

  104. 104.

    Glykys J., Mann E.O., Mody I. Which GABAA receptor subunits are necessary for tonic inhibition in the hippocampus? J. Neurosci.: Off. J. Soc. Neurosci. 2008;28:1421-1426.

    Not in our library10.1523/jneurosci.4751-07.2008

  105. 105.

    Gold B.I., Bowers M.B., Roth R.H., Sweeney D.W. GABA levels in CSF of patients with psychiatric disorders. Am. J. Psychiatry. 1980;137:362-364.

    Not in our library10.1176/ajp.137.3.362

  106. 106.

    Griffin L.D., Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA. 1999;96:13512-13517.

    Not in our library10.1073/pnas.96.23.13512

  107. 107.

    Grobin A.C., Morrow A.L. 3Alpha-hydroxy-5alpha-pregnan-20-one levels and GABAA receptor-mediated 36Cl(−) flux across development in rat cerebral cortex. Brain Res. Dev. Brain Res. 2001;131:31-39.

    Not in our library10.1016/s0165-3806(01)00242-5

  108. 108.

    Grobin A.C., Heenan E.J., Lieberman J.A., Morrow A.L. Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex. J. Neurosci.: Off. J. Soc. Neurosci. 2003;23:1832-1839.

    Not in our library10.1523/jneurosci.23-05-01832.2003

  109. 109.

    Grobin A.C., Lieberman J.A., Morrow A.L. Perinatal flunitrazepam exposure causes persistent alteration of parvalbumin-immunoreactive interneuron localization in rat prefrontal cortex. Neurosci. Lett. 2004;359:9-12.

    Not in our library10.1016/j.neulet.2003.12.124

  110. 110.

    Guidotti A., Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol. Psychiatry. 1998;44:865-873.

    Not in our library10.1016/s0006-3223(98)00070-5

  111. 111.

    Guilloux J.P., Douillard-Guilloux G., Kota R., Wang X., Gardier A.M., Martinowich K., Tseng G.C., Lewis D.A., Sibille E. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Molecular psychiatry. 2012;17:1130-1142.

    Not in our library10.1038/mp.2011.113

  112. 112.

    Gunn B.G., Brown A.R., Lambert J.J., Belelli D. Neurosteroids and GABAA Receptor Interactions: a Focus on Stress. Frontiers Neurosci. 2011;5:131.

    Not in our library10.3389/fnins.2011.00131

  113. 113.

    Gunn B.G., Cunningham L., Cooper M.A., Corteen N.L., Seifi M., Swinny J.D., Lambert J.J., Belelli D. Dysfunctional astrocytic and synaptic regulation of hypothalamic glutamatergic transmission in a mouse model of early-life adversity: relevance to neurosteroids and programming of the stress response. J. Neurosci.: Off. J. Soc. Neurosci. 2013;33:19534-19554.

    Not in our library10.1523/jneurosci.1337-13.2013

  114. 114.

    Harrison N.L., Simmonds M.A. Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res. 1984;323:287-292.

    Not in our library10.1016/0006-8993(84)90299-3

  115. 115.

    Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 2007;64:193-200.

    Not in our library10.1001/archpsyc.64.2.193

  116. 116.

    Heim C., Shugart M., Craighead W.E., Nemeroff C.B. Neurobiological and psychiatric consequences of child abuse and neglect. Dev. Psychobiol. 2010;52:671-690.

    Not in our library10.1002/dev.20494

  117. 117.

    Heine V.M., Maslam S., Zareno J., Joels M., Lucassen P.J. Suppressed proliferation and apoptotic changes in the rat dentate gyrus after acute and chronic stress are reversible. Eur. J. Neurosci. 2004;19:131-144.

    Not in our library10.1046/j.1460-9568.2003.03100.x

  118. 118.

    Helmeke C., Ovtscharoff W., Poeggel G., Braun K. Imbalance of immunohistochemically characterized interneuron populations in the adolescent and adult rodent medial prefrontal cortex after repeated exposure to neonatal separation stress. Neuroscience. 2008;152:18-28.

    Not in our library10.1016/j.neuroscience.2007.12.023

  119. 119.

    Herd M.B., Belelli D., Lambert J.J. Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors. Pharmacol. Ther. 2007;116:20-34.

    Not in our library10.1016/j.pharmthera.2007.03.007

  120. 120.

    Herd M.B., Haythornthwaite A.R., Rosahl T.W., Wafford K.A., Homanics G.E., Lambert J.J., Belelli D. The expression of GABAA beta subunit isoforms in synaptic and extrasynaptic receptor populations of mouse dentate gyrus granule cells. J. Physiol. 2008;586:989-1004.

    Not in our library10.1113/jphysiol.2007.146746

  121. 121.

    Herd M.B., Brown A.R., Lambert J.J., Belelli D. Extrasynaptic GABAA receptors couple presynaptic activity to postsynaptic inhibition in the somatosensory thalamus. J. Neurosci.: Off. J. Soc. Neurosci. 2013;33:14850-14868.

    Not in our library10.1523/jneurosci.1174-13.2013

  122. 122.

    Herman J.P., Cullinan W.E. Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis. Trends Neurosci. 1997;20:78-84.

    Not in our library10.1016/s0166-2236(96)10069-2

  123. 123.

    Herman J.P., Eyigor O., Ziegler D.R., Jennes L. Expression of ionotropic glutamate receptor subunit mRNAs in the hypothalamic paraventricular nucleus of the rat. J. Comp. Neurol. 2000;422:352-362.

    Not in our library

  124. 124.

    Herman J.P., Cullinan W.E., Ziegler D.R., Tasker J.G. Role of the paraventricular nucleus microenvironment in stress integration. Eur. J. Neurosci. 2002;16:381-385.

    Not in our library10.1046/j.1460-9568.2002.02133.x

  125. 125.

    Herman J.P., Figueiredo H., Mueller N.K., Ulrich-Lai Y., Ostrander M.M., Choi D.C., Cullinan W.E. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo–pituitary–adrenocortical responsiveness. Front. Neuroendocrinol. 2003;24:151-180.

    Not in our library10.1016/j.yfrne.2003.07.001

  126. 126.

    Herman M.A., Contet C., Justice N.J., Vale W., Roberto M. Novel subunit-specific tonic GABA currents and differential effects of ethanol in the central amygdala of CRF receptor-1 reporter mice. J. Neurosci.: Off. J. Soc. Neurosci. 2013;33:3284-3298.

    Not in our library10.1523/jneurosci.2490-12.2013

  127. 127.

    Hewitt S.A., Wamsteeker J.I., Kurz E.U., Bains J.S. Altered chloride homeostasis removes synaptic inhibitory constraint of the stress axis. Nat. Neurosci. 2009;12:438-443.

    Not in our library10.1038/nn.2274

  128. 128.

    Hortnagl H., Tasan R.O., Wieselthaler A., Kirchmair E., Sieghart W., Sperk G. Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neuroscience. 2013;236:345-372.

    Not in our library10.1016/j.neuroscience.2013.01.008

  129. 129.

    Hosie A.M., Wilkins M.E., da Silva H.M., Smart T.G. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature. 2006;444:486-489.

    Not in our library10.1038/nature05324

  130. 130.

    Hsu F.C., Zhang G.J., Raol Y.S., Valentino R.J., Coulter D.A., Brooks-Kayal A.R. Repeated neonatal handling with maternal separation permanently alters hippocampal GABAA receptors and behavioral stress responses. Proc. Natl. Acad. Sci. USA. 2003;100:12213-12218.

    Not in our library10.1073/pnas.2131679100

  131. 131.

    Ivy A.S., Rex C.S., Chen Y., Dube C., Maras P.M., Grigoriadis D.E., Gall C.M., Lynch G., Baram T.Z. Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors. J. Neurosci.: Off. J. Soc. Neurosci. 2010;30:13005-13015.

    Not in our library10.1523/jneurosci.1784-10.2010

  132. 132.

    Izumi Y., Murayama K., Tokuda K., Krishnan K., Covey D.F., Zorumski C.F. GABAergic neurosteroids mediate the effects of ethanol on long-term potentiation in rat hippocampal slices. Eur. J. Neurosci. 2007;26:1881-1888.

    Not in our library10.1111/j.1460-9568.2007.05809.x

  133. 133.

    Izumi Y., Tokuda K., Zorumski C.F. Long-term potentiation inhibition by low-level N-methyl-d-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus. 2008;18:258-265.

    Not in our library10.1002/hipo.20383

  134. 134.

    Kalk N.J., Owen D.R., Tyacke R.J., Reynolds R., Rabiner E.A., Lingford-hughes A.R., Parker C.A. Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies? Synapse. 2013;67:909-912.

    Not in our library10.1002/syn.21681

  135. 135.

    Karavolas H.J., Hodges D.R. Neuroendocrine metabolism of progesterone and related progestins. Ciba Found. Symp. 1990;153:22-44.

    Not in our library10.1002/9780470513989.ch3

  136. 136.
  137. 137.

    Kehoe P., Mallinson K., McCormick C.M., Frye C.A. Central allopregnanolone is increased in rat pups in response to repeated, short episodes of neonatal isolation. Brain Res. Dev. Brain Res. 2000;124:133-136.

    Not in our library10.1016/s0165-3806(00)00106-1

  138. 138.

    Kempermann G., Wiskott L., Gage F.H. Functional significance of adult neurogenesis. Curr. Opin. Neurobiol. 2004;14:186-191.

    Not in our library10.1016/j.conb.2004.03.001

  139. 139.

    Kheirbek M.A., Klemenhagen K.C., Sahay A., Hen R. Neurogenesis and generalization: a new approach to stratify and treat anxiety disorders. Nat. Neurosci. 2012;15:1613-1620.

    Not in our library10.1038/nn.3262

  140. 140.

    Khisti R.T., VanDoren M.J., O’Buckley T., Morrow A.L. Neuroactive steroid 3 alpha-hydroxy-5 alpha-pregnan-20-one modulates ethanol-induced loss of righting reflex in rats. Brain Res. 2003;980:255-265.

    Not in our library10.1016/s0006-8993(03)02978-0

  141. 141.

    Kimoto T., Tsurugizawa T., Ohta Y., Makino J., Tamura H., Hojo Y., Takata N., Kawato S. Neurosteroid synthesis by cytochrome p450-containing systems localized in the rat brain hippocampal neurons: N-methyl-d-aspartate and calcium-dependent synthesis. Endocrinology. 2001;142:3578-3589.

    Not in our library10.1210/endo.142.8.8327

  142. 142.

    King S.R., Manna P.R., Ishii T., Syapin P.J., Ginsberg S.D., Wilson K., Walsh L.P., Parker K.L., Stocco D.M., Smith R.G., Lamb D.J. An essential component in steroid synthesis, the steroidogenic acute regulatory protein, is expressed in discrete regions of the brain. J. Neurosci.: Off. J. Soc. Neurosci. 2002;22:10613-10620.

    Not in our library10.1523/jneurosci.22-24-10613.2002

  143. 143.

    Klausberger T., Somogyi P. Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. Science. 2008;321:53-57.

    Not in our library10.1126/science.1149381

  144. 144.

    Klausberger T., Roberts J.D., Somogyi P. Cell type- and input-specific differences in the number and subtypes of synaptic GABAA receptors in the hippocampus. J. Neurosci.: Off. J. Soc. Neurosci. 2002;22:2513-2521.

    Not in our library10.1523/jneurosci.22-07-02513.2002

  145. 145.
  146. 146.

    Korosi A., Shanabrough M., McClelland S., Liu Z.W., Borok E., Gao X.B., Horvath T.L., Baram T.Z. Early-life experience reduces excitation to stress-responsive hypothalamic neurons and reprograms the expression of corticotropin-releasing hormone. J. Neurosci.: Off. J. Soc. Neurosci. 2010;30:703-713.

    Not in our library10.1523/jneurosci.4214-09.2010

  147. 147.

    Korosi A., Naninck E.F., Oomen C.A., Schouten M., Krugers H., Fitzsimons C., Lucassen P.J. Early-life stress mediated modulation of adult neurogenesis and behavior. Behav. Brain Res. 2012;227:400-409.

    Not in our library10.1016/j.bbr.2011.07.037

  148. 148.

    Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry. 2002;7(Suppl 1):S71-S80.

    Not in our library10.1038/sj.mp.4001021

  149. 149.

    Kuhlmann A.C., Guilarte T.R. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J. Neurochem. 2000;74:1694-1704.

    Not in our library10.1046/j.1471-4159.2000.0741694.x

  150. 150.

    Lambert J.J., Belelli D., Hill-Venning C., Peters J.A. Neurosteroids and GABAA receptor function. Trends Pharmacol. Sci. 1995;16:295-303.

    Not in our library10.1016/s0165-6147(00)89058-6

  151. 151.

    Lambert J.J., Cooper M.A., Simmons R.D., Weir C.J., Belelli D. Neurosteroids: endogenous allosteric modulators of GABAA receptors. Psychoneuroendocrinology. 2009;34(Suppl 1):S48-S58.

    Not in our library10.1016/j.psyneuen.2009.08.009

  152. 152.

    Lehmann J., Pryce C.R., Jongen-Relo A.L., Stohr T., Pothuizen H.H., Feldon J. Comparison of maternal separation and early handling in terms of their neurobehavioral effects in aged rats. Neurobiol. Aging. 2002;23:457-466.

    Not in our library10.1016/s0197-4580(01)00320-7

  153. 153.

    Lemaire V., Koehl M., Le Moal M., Abrous D.N. Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. Proc. Natl. Acad. Sci. USA. 2000;97:11032-11037.

    Not in our library10.1073/pnas.97.20.11032

  154. 154.

    Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35:57-67.

    Not in our library10.1016/j.tins.2011.10.004

  155. 155.

    Li X., Bertics P.J., Karavolas H.J. Regional distribution of cytosolic and particulate 5alpha-dihydroprogesterone 3alpha-hydroxysteroid oxidoreductases in female rat brain. J. Steroid Biochem. Mol. Biol. 1997;60:311-318.

    Not in our library10.1016/s0960-0760(96)00195-1

  156. 156.

    Liu D., Diorio J., Tannenbaum B., Caldji C., Francis D., Freedman A., Sharma S., Pearson D., Plotsky P.M., Meaney M.J. Maternal care, hippocampal glucocorticoid receptors, and hypothalamic–pituitary–adrenal responses to stress. Science. 1997;277:1659-1662.

    Not in our library10.1126/science.277.5332.1659

  157. 157.

    Liu R.J., Lee F.S., Li X.Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry. 2012;71:996-1005.

    Not in our library10.1016/j.biopsych.2011.09.030

  158. 158.

    Loi M., Koricka S., Lucassen P.J., Joels M. Age- and sex-dependent effects of early life stress on hippocampal neurogenesis. Front. Endocrinol. 2014;5:13.

    Not in our library10.3389/fendo.2014.00013

  159. 159.

    Longone P., Rupprecht R., Manieri G.A., Bernardi G., Romeo E., Pasini A. The complex roles of neurosteroids in depression and anxiety disorders. Neurochem. Int. 2008;52:596-601.

    Not in our library10.1016/j.neuint.2007.10.001

  160. 160.

    Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J.A., Fritschy J.M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000;290:131-134.

    Not in our library10.1126/science.290.5489.131

  161. 161.

    Lucassen P.J., Bosch O.J., Jousma E., Kromer S.A., Andrew R., Seckl J.R., Neumann I.D. Prenatal stress reduces postnatal neurogenesis in rats selectively bred for high, but not low, anxiety: possible key role of placental 11beta-hydroxysteroid dehydrogenase type 2. Eur. J. Neurosci. 2009;29:97-103.

    Not in our library10.1111/j.1460-9568.2008.06543.x

  162. 162.

    Lupien S.J., McEwen B.S., Gunnar M.R., Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 2009;10:434-445.

    Not in our library10.1038/nrn2639

  163. 163.

    Luscher B., Shen Q., Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol. Psychiatry. 2011;16:383-406.

    Not in our library10.1038/mp.2010.120

  164. 164.

    Maciag D., Hughes J., O’Dwyer G., Pride Y., Stockmeier C.A., Sanacora G., Rajkowska G. Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol. Psychiatry. 2010;67:465-470.

    Not in our library10.1016/j.biopsych.2009.10.027

  165. 165.

    Maeda J., Higuchi M., Inaji M., Ji B., Haneda E., Okauchi T., Zhang M.R., Suzuki K., Suhara T. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res. 2007;1157:100-111.

    Not in our library10.1016/j.brainres.2007.04.054

  166. 166.

    Maguire J., Mody I. GABAAR plasticity during pregnancy: relevance to postpartum depression. Neuron. 2008;59:207-213.

    Not in our library10.1016/j.neuron.2008.06.019

  167. 167.

    Maguire E.P., Macpherson T., Swinny J.D., Dixon C.I., Herd M.B., Belelli D., Stephens D.N., King S.L., Lambert J.J. Tonic inhibition of accumbal spiny neurons by extrasynaptic alpha4betadelta GABAA receptors modulates the actions of psychostimulants. J. Neurosci.: Off. J. Soc. Neurosci. 2014;34:823-838.

    Not in our library10.1523/jneurosci.3232-13.2014

  168. 168.

    Maitra R., Reynolds J.N. Modulation of GABAA receptor function by neuroactive steroids: evidence for heterogeneity of steroid sensitivity of recombinant GABAA receptor isoforms. Can. J. Physiol. Pharmacol. 1998;76:909-920.

    Not in our library10.1139/cjpp-76-9-909

  169. 169.

    Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci.: Off. J. Soc. Neurosci. 2000;20:9104-9110.

    Not in our library10.1523/jneurosci.20-24-09104.2000

  170. 170.

    Markram H., Toledo-Rodriguez M., Wang Y., Gupta A., Silberberg G., Wu C. Interneurons of the neocortical inhibitory system. Nat. Rev. Neurosci. 2004;5:793-807.

    Not in our library10.1038/nrn1519

  171. 171.

    Marowsky A., Rudolph U., Fritschy J.M., Arand M. Tonic inhibition in principal cells of the amygdala: a central role for alpha3 subunit-containing GABAA receptors. J. Neurosci.: Off. J. Soc. Neurosci. 2012;32:8611-8619.

    Not in our library10.1523/jneurosci.4404-11.2012

  172. 172.

    Martin-Garcia E., Darbra S., Pallares M. Neonatal finasteride induces anxiogenic-like profile and deteriorates passive avoidance in adulthood after intrahippocampal neurosteroid administration. Neuroscience. 2008;154:1497-1505.

    Not in our library10.1016/j.neuroscience.2008.04.062

  173. 173.

    Martisova E., Solas M., Horrillo I., Ortega J.E., Meana J.J., Tordera R.M., Ramirez M.J. Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus. Neuropharmacology. 2012;62:1944-1953.

    Not in our library10.1016/j.neuropharm.2011.12.019

  174. 174.

    Matsumoto K., Uzunova V., Pinna G., Taki K., Uzunov D.P., Watanabe H., Mienville J.M., Guidotti A., Costa E. Permissive role of brain allopregnanolone content in the regulation of pentobarbital-induced righting reflex loss. Neuropharmacology. 1999;38:955-963.

    Not in our library10.1016/s0028-3908(99)00018-0

  175. 175.

    McCauley L.D., Lan N.C., Tomich J.M., Shively J.E., Gee K.W., Biggio G., Concas A., Costa E. Peripheral-type benzodiazepine receptors and the regulation of steroidogenesis in rat brain mitochondria. GABAergic Synaptic Transmission. 1992;143-147.

    Not in our library

  176. 176.

    McEwen B.S. Early life influences on life-long patterns of behavior and health. Ment. Retard. Dev. Disabil. Res. Rev. 2003;9:149-154.

    Not in our library10.1002/mrdd.10074

  177. 177.

    McEwen B.S., Morrison J.H. The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course. Neuron. 2013;79:16-29.

    Not in our library10.1016/j.neuron.2013.06.028

  178. 178.

    Meaney M.J. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu. Rev. Neurosci. 2001;24:1161-1192.

    Not in our library10.1146/annurev.neuro.24.1.1161

  179. 179.

    Melcangi R.C., Celotti F., Castano P., Martini L. Differential localization of the 5 alpha-reductase and the 3 alpha-hydroxysteroid dehydrogenase in neuronal and glial cultures. Endocrinology. 1993;132:1252-1259.

    Not in our library10.1210/endo.132.3.8440186

  180. 180.

    Mellon S.H., Deschepper C.F. Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res. 1993;629:283-292.

    Not in our library10.1016/0006-8993(93)91332-m

  181. 181.

    Mennerick S., He Y., Jiang X., Manion B.D., Wang M., Shute A., Benz A., Evers A.S., Covey D.F., Zorumski C.F. Selective antagonism of 5alpha-reduced neurosteroid effects at GABAA receptors. Mol. Pharmacol. 2004;65:1191-1197.

    Not in our library10.1124/mol.65.5.1191

  182. 182.

    Miklos I.H., Kovacs K.J. GABAergic innervation of corticotropin-releasing hormone (CRH)-secreting parvocellular neurons and its plasticity as demonstrated by quantitative immunoelectron microscopy. Neuroscience. 2002;113:581-592.

    Not in our library10.1016/s0306-4522(02)00147-1

  183. 183.

    Miklos I.H., Kovacs K.J. Reorganization of synaptic inputs to the hypothalamic paraventricular nucleus during chronic psychogenic stress in rats. Biol. Psychiatry. 2012;71:301-308.

    Not in our library10.1016/j.biopsych.2011.10.027

  184. 184.

    Millstein R.A., Holmes A. Effects of repeated maternal separation on anxiety- and depression-related phenotypes in different mouse strains. Neurosci. Biobehav. Rev. 2007;31:3-17.

    Not in our library10.1016/j.neubiorev.2006.05.003

  185. 185.

    Mirescu C., Peters J.D., Gould E. Early life experience alters response of adult neurogenesis to stress. Nat. Neurosci. 2004;7:841-846.

    Not in our library10.1038/nn1290

  186. 186.

    Mitev Y.A., Darwish M., Wolf S.S., Holsboer F., Almeida O.F., Patchev V.K. Gender differences in the regulation of 3 alpha-hydroxysteroid dehydrogenase in rat brain and sensitivity to neurosteroid-mediated stress protection. Neuroscience. 2003;120:541-549.

    Not in our library10.1016/s0306-4522(03)00287-2

  187. 187.

    Modol L., Darbra S., Vallee M., Pallares M. Alteration of neonatal Allopregnanolone levels affects exploration, anxiety, aversive learning and adult behavioural response to intrahippocampal neurosteroids. Behav. Brain Res. 2013;241:96-104.

    Not in our library10.1016/j.bbr.2012.11.043

  188. 188.

    Mohler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012;62:42-53.

    Not in our library10.1016/j.neuropharm.2011.08.040

  189. 189.

    Morrow A.L., Porcu P., Boyd K.N., Grant K.A. Hypothalamic–pituitary–adrenal axis modulation of GABAergic neuroactive steroids influences ethanol sensitivity and drinking behavior. Dialogues Clin. Neurosci. 2006;8:463-477.

    Not in our library10.31887/dcns.2006.8.4/amorrow

  190. 190.

    Morrow A.L., Biggio G., Serra M., Becker H.C., Lopez M.F., Porcu P., Alward S.E., O’Buckley T.K. The role of neuroactive steroids in ethanol/stress interactions: proceedings of symposium VII at the Volterra conference on alcohol and stress, May 2008. Alcohol. 2009;43:521-530.

    Not in our library10.1016/j.alcohol.2009.04.002

  191. 191.

    Murphy B.E.P., Abbott F.V., Allison C.M., Watts C., Ghadirian A.M. Elevated levels of some neuroactive progesterone metabolites, particularly isopregnanolone, in women with chronic fatigue syndrome. Psychoneuroendocrinology. 2004;29:245-268.

    Not in our library10.1016/s0306-4530(03)00026-x

  192. 192.

    Nani F., Bright D.P., Revilla-Sanchez R., Tretter V., Moss S.J., Smart T.G. Tyrosine phosphorylation of GABAA receptor gamma2-subunit regulates tonic and phasic inhibition in the thalamus. J. Neurosci.: Off. J. Soc. Neurosci. 2013;33:12718-12727.

    Not in our library10.1523/jneurosci.0388-13.2013

  193. 193.

    Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010;13:1161-1169.

    Not in our library10.1038/nn.2647

  194. 194.

    Niciu M.J., Henter I.D., Luckenbaugh D.A., Zarate C.A., Charney D.S. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu. Rev. Pharmacol. Toxicol. 2014;54:119-139.

    Not in our library10.1146/annurev-pharmtox-011613-135950

  195. 195.

    Nin M.S., Martinez L.A., Pibiri F., Nelson M., Pinna G. Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression. Front. Endocrinol. 2011;2:73.

    Not in our library10.3389/fendo.2011.00073

  196. 196.

    Nothdurfter C., Rammes G., Baghai T.C., Schule C., Schumacher M., Papadopoulos V., Rupprecht R. Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile. J. Neuroendocrinol. 2012;24:82-92.

    Not in our library10.1111/j.1365-2826.2011.02166.x

  197. 197.

    Nusser Z., Mody I. Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. J. Neurophysiol. 2002;87:2624-2628.

    Not in our library10.1152/jn.2002.87.5.2624

  198. 198.

    Nyiri G., Freund T.F., Somogyi P. Input-dependent synaptic targeting of alpha(2)-subunit-containing GABAA receptors in synapses of hippocampal pyramidal cells of the rat. The European journal of neuroscience. 2001;13:428-442.

    Not in our library10.1046/j.1460-9568.2001.01407.x

  199. 199.

    Olsen R.W., Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function, Update. Pharmacol. Rev. 2008;60:243-260.

    Not in our library10.1124/pr.108.00505

  200. 200.

    Olsen R.W., Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 2009;56:141-148.

    Not in our library10.1016/j.neuropharm.2008.07.045

  201. 201.

    Oomen C.A., Mayer J.L., de Kloet E.R., Joels M., Lucassen P.J. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the reduction in neurogenesis after chronic stress. Eur. J. Neurosci. 2007;26:3395-3401.

    Not in our library10.1111/j.1460-9568.2007.05972.x

  202. 202.

    Oomen C.A., Soeters H., Audureau N., Vermunt L., van Hasselt F.N., Manders E.M., Joels M., Lucassen P.J., Krugers H. Severe early life stress hampers spatial learning and neurogenesis, but improves hippocampal synaptic plasticity and emotional learning under high-stress conditions in adulthood. J. Neurosci.: Off. J. Soc. Neurosci. 2010;30:6635-6645.

    Not in our library10.1523/jneurosci.0247-10.2010

  203. 203.

    Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 1991;43:425-473.

    Not in our library

  204. 204.

    Owens M.J., Ritchie J.C., Nemeroff C.B. 5 alpha-pregnane-3 alpha, 21-diol-20-one (THDOC) attenuates mild stress-induced increases in plasma corticosterone via a non-glucocorticoid mechanism: comparison with alprazolam. Brain Res. 1992;573:353-355.

    Not in our library10.1016/0006-8993(92)90788-b

  205. 205.

    Own L.S., Patel P.D. Maternal behavior and offspring resiliency to maternal separation in C57Bl/6 mice. Horm. Behav. 2013;63:411-417.

    Not in our library10.1016/j.yhbeh.2012.11.010

  206. 206.

    Padberg F., di Michele F., Zwanzger P., Romeo E., Bernardi G., Schule C., Baghai T.C., Ella R., Pasini A., Rupprecht R. Plasma concentrations of neuroactive steroids before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol. 2002;27:874-878.

    Not in our library10.1016/s0893-133x(02)00355-x

  207. 207.

    Panzanelli P., Gunn B.G., Schlatter M.C., Benke D., Tyagarajan S.K., Scheiffele P., Belelli D., Lambert J.J., Rudolph U., Fritschy J.M. Distinct mechanisms regulate GABAA receptor and gephyrin clustering at perisomatic and axo-axonic synapses on CA1 pyramidal cells. J. Physiol. 2011;589:4959-4980.

    Not in our library10.1113/jphysiol.2011.216028

  208. 208.

    Patchev V.K., Shoaib M., Holsboer F., Almeida O.F. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience. 1994;62:265-271.

    Not in our library10.1016/0306-4522(94)90330-1

  209. 209.

    Patchev V.K., Hassan A.H., Holsboer D.F., Almeida O.F. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol. 1996;15:533-540.

    Not in our library10.1016/s0893-133x(96)00096-6

  210. 210.

    Patchev V.K., Montkowski A., Rouskova D., Koranyi L., Holsboer F., Almeida O.F. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J. Clin. Investig. 1997;99:962-966.

    Not in our library10.1172/jci119261

  211. 211.

    Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J.: Off. Pub. Feder. Am. Soc. Exp. Biol. 1992;6:2311-2322.

    Not in our library

  212. 212.

    Payne J.L., Palmer J.T., Joffe H. A reproductive subtype of depression: conceptualizing models and moving toward etiology. Harvard Rev. Psychiatry. 2009;17:72-86.

    Not in our library10.1080/10673220902899706

  213. 213.

    Petrik D., Lagace D.C., Eisch A.J. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building? Neuropharmacology. 2012;62:21-34.

    Not in our library10.1016/j.neuropharm.2011.09.003

  214. 214.

    Petty F., Schlesser M.A. Plasma GABA in affective illness. A preliminary investigation. J. Affect. Disord. 1981;3:339-343.

    Not in our library10.1016/0165-0327(81)90003-3

  215. 215.

    Pibiri F., Nelson M., Guidotti A., Costa E., Pinna G. Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: a model relevant for posttraumatic stress disorder. Proc. Natl. Acad. Sci. USA. 2008;105:5567-5572.

    Not in our library10.1073/pnas.0801853105

  216. 216.

    Pilc A., Wieronska J.M., Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology. Biol. Psychiatry. 2013;73:1125-1132.

    Not in our library10.1016/j.biopsych.2013.01.021

  217. 217.

    Pinna G. In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behav. Pharmacol. 2010;21:438-450.

    Not in our library10.1097/fbp.0b013e32833d8ba0

  218. 218.

    Pinna G., Costa E., Guidotti A. Fluoxetine and norfluoxetine stereospecifically facilitate pentobarbital sedation by increasing neurosteroids. Proc. Natl. Acad. Sci. USA. 2004;101:6222-6225.

    Not in our library10.1073/pnas.0401479101

  219. 219.

    Popoli M., Yan Z., McEwen B.S., Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 2012;13:22-37.

    Not in our library10.1038/nrn3138

  220. 220.

    Priebe K., Romeo R.D., Francis D.D., Sisti H.M., Mueller A., McEwen B.S., Brake W.G. Maternal influences on adult stress and anxiety-like behavior in C57BL/6J and BALB/cJ mice: a cross-fostering study. Dev. Psychobiol. 2005;47:398-407.

    Not in our library10.1002/dev.20098

  221. 221.

    Pryce C.R., Bettschen D., Feldon J. Comparison of the effects of early handling and early deprivation on maternal care in the rat. Dev. Psychobiol. 2001;38:239-251.

    Not in our library10.1002/dev.1018

  222. 222.

    Puia G., Mienville J.M., Matsumoto K., Takahata H., Watanabe H., Costa E., Guidotti A. On the putative physiological role of allopregnanolone on GABAA receptor function. Neuropharmacology. 2003;44:49-55.

    Not in our library10.1016/s0028-3908(02)00341-6

  223. 223.

    Purdy R.H., Morrow A.L., Moore P.H., Paul S.M. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. USA. 1991;88:4553-4557.

    Not in our library10.1073/pnas.88.10.4553

  224. 224.

    Quast C., Reif A., Bruckl T., Pfister H., Weber H., Mattheisen M., Cichon S., Lang T., Hamm A., Fehm L., Strohle A., Arolt V., Domschke K., Kircher T., Wittchen H.U., Pauli P., Gerlach A.L., Alpers G.W., Deckert J., Rupprecht R., Binder E.B., Erhardt A. Gender-specific association of variants in the Akr1c1 gene with dimensional anxiety in patients with panic disorder: additional evidence for the importance of neurosteroids in anxiety? Depression Anx. 2014.

    Not in our library10.1002/da.22229

  225. 225.

    Racagni G., Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin. Neurosci. 2008;10:385-400.

    Not in our library10.31887/dcns.2008.10.4/gracagni

  226. 226.
  227. 227.

    Radley J.J., Sawchenko P.E. A common substrate for prefrontal and hippocampal inhibition of the neuroendocrine stress response. J. Neurosci.: Off. J. Soc. Neurosci. 2011;31:9683-9695.

    Not in our library10.1523/jneurosci.6040-10.2011

  228. 228.

    Radley J.J., Gosselink K.L., Sawchenko P.E. A discrete GABAergic relay mediates medial prefrontal cortical inhibition of the neuroendocrine stress response. J. Neurosci.: Off. J. Soc. Neurosci. 2009;29:7330-7340.

    Not in our library10.1523/jneurosci.5924-08.2009

  229. 229.

    Rajkowska G., O’Dwyer G., Teleki Z., Stockmeier C.A., Miguel-Hidalgo J.J. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol. 2007;32:471-482.

    Not in our library10.1038/sj.npp.1301234

  230. 230.

    Reddy D.S. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? Trends Pharmacol. Sci. 2003;24:103-106.

    Not in our library10.1016/s0165-6147(03)00023-3

  231. 231.

    Regev L., Baram T.Z. Corticotropin releasing factor in neuroplasticity. Front. Neuroendocrinol. 2014;35:171-179.

    Not in our library10.1016/j.yfrne.2013.10.001

  232. 232.

    Rice C.J., Sandman C.A., Lenjavi M.R., Baram T.Z. A novel mouse model for acute and long-lasting consequences of early life stress. Endocrinology. 2008;149:4892-4900.

    Not in our library10.1210/en.2008-0633

  233. 233.

    Roland B.L., Sawchenko P.E. Local origins of some GABAergic projections to the paraventricular and supraoptic nuclei of the hypothalamus in the rat. J. Comp. Neurol. 1993;332:123-143.

    Not in our library10.1002/cne.903320109

  234. 234.

    Romeo E., Strohle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry. 1998;155:910-913.

    Not in our library10.1176/ajp.155.7.910

  235. 235.

    Roozendaal B., McEwen B.S., Chattarji S. Stress, memory and the amygdala. Nat. Rev. Neurosci. 2009;10:423-433.

    Not in our library10.1038/nrn2651

  236. 236.

    Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discovery. 2011;10:685-697.

    Not in our library10.1038/nrd3502

  237. 237.

    Rudolph U., Mohler H. GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol. 2014;54:483-507.

    Not in our library10.1146/annurev-pharmtox-011613-135947

  238. 238.

    Rupprecht R., Rammes G., Eser D., Baghai T.C., Schule C., Nothdurfter C., Troxler T., Gentsch C., Kalkman H.O., Chaperon F., Uzunov V., McAllister K.H., Bertaina-Anglade V., La Rochelle C.D., Tuerck D., Floesser A., Kiese B., Schumacher M., Landgraf R., Holsboer F., Kucher K. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science. 2009;325:490-493.

    Not in our library10.1126/science.1175055

  239. 239.

    Rupprecht R., Papadopoulos V., Rammes G., Baghai T.C., Fan J., Akula N., Groyer G., Adams D., Schumacher M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discovery. 2010;9:971-988.

    Not in our library10.1038/nrd3295

  240. 240.

    Russo S.J., Nestler E.J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 2013;14:609-625.

    Not in our library10.1038/nrn3381

  241. 241.

    Saalmann Y.B., Kirkcaldie M.T., Waldron S., Calford M.B. Cellular distribution of the GABAA receptor-modulating 3alpha-hydroxy, 5alpha-reduced pregnane steroids in the adult rat brain. J. Neuroendocrinol. 2007;19:272-284.

    Not in our library10.1111/j.1365-2826.2006.01527.x

  242. 242.

    Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., Berman R.M., Charney D.S., Krystal J.H. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1999;56:1043-1047.

    Not in our library10.1001/archpsyc.56.11.1043

  243. 243.

    Sanacora G., Mason G.F., Krystal J.H. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit. Rev. Neurobiol. 2000;14:23-45.

    Not in our library10.1615/critrevneurobiol.v14.i1.20

  244. 244.

    Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., Krystal J.H., Mason G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry. 2004;61:705-713.

    Not in our library10.1001/archpsyc.61.7.705

  245. 245.

    Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63-77.

    Not in our library10.1016/j.neuropharm.2011.07.036

  246. 246.

    Sanchez M.M., Ladd C.O., Plotsky P.M. Early adverse experience as a developmental risk factor for later psychopathology: evidence from rodent and primate models. Dev. Psychopathol. 2001;13:419-449.

    Not in our library10.1017/s0954579401003029

  247. 247.

    Sanchez P., Torres J.M., Olmo A., O’Valle F., Ortega E. Effects of environmental stress on mRNA and protein expression levels of steroid 5alpha-Reductase isozymes in adult rat brain. Horm. Behav. 2009;56:348-353.

    Not in our library10.1016/j.yhbeh.2009.07.001

  248. 248.

    Sanna E., Cuccheddu T., Serra M., Concas A., Biggio G. Carbon dioxide inhalation reduces the function of GABAA receptors in the rat brain. Eur. J. Pharmacol. 1992;216:457-458.

    Not in our library10.1016/0014-2999(92)90447-c

  249. 249.

    Sanna E., Talani G., Busonero F., Pisu M.G., Purdy R.H., Serra M., Biggio G. Brain steroidogenesis mediates ethanol modulation of GABAA receptor activity in rat hippocampus. J. Neurosci.: Off. J. Soc. Neurosci. 2004;24:6521-6530.

    Not in our library10.1523/jneurosci.0075-04.2004

  250. 250.

    Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809.

    Not in our library10.1126/science.1083328

  251. 251.

    Sapolsky R.M., Meaney M.J. Maturation of the adrenocortical stress response: neuroendocrine control mechanisms and the stress hyporesponsive period. Brain Res. 1986;396:64-76.

    Not in our library10.1016/s0006-8993(86)80190-1

  252. 252.

    Sarkar J., Wakefield S., MacKenzie G., Moss S.J., Maguire J. Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors. J. Neurosci.: Off. J. Soc. Neurosci. 2011;31:18198-18210.

    Not in our library10.1523/jneurosci.2560-11.2011

  253. 253.

    Schmidt M.V. Molecular mechanisms of early life stress–lessons from mouse models. Neurosci. Biobehav. Rev. 2010;34:845-852.

    Not in our library10.1016/j.neubiorev.2009.05.002

  254. 254.

    Schmidt M., Enthoven L., van Woezik J.H., Levine S., de Kloet E.R., Oitzl M.S. The dynamics of the hypothalamic-pituitary-adrenal axis during maternal deprivation. J. Neuroendocrinol. 2004;16:52-57.

    Not in our library10.1111/j.1365-2826.2004.01123.x

  255. 255.

    Schule C., di Michele F., Baghai T., Romeo E., Bernardi G., Zwanzger P., Padberg F., Pasini A., Rupprecht R. Influence of sleep deprivation on neuroactive steroids in major depression. Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol. 2003;28:577-581.

    Not in our library10.1038/sj.npp.1300084

  256. 256.

    Schule C., Romeo E., Uzunov D.P., Eser D., di Michele F., Baghai T.C., Pasini A., Schwarz M., Kempter H., Rupprecht R. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol. Psychiatry. 2006;11:261-272.

    Not in our library10.1038/sj.mp.4001782

  257. 257.

    Schule C., Nothdurfter C., Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog. Neurobiol. 2014;113:79-87.

    Not in our library10.1016/j.pneurobio.2013.09.003

  258. 258.

    Scimemi A., Semyanov A., Sperk G., Kullmann D.M., Walker M.C. Multiple and plastic receptors mediate tonic GABAA receptor currents in the hippocampus. J. Neurosci.: Off. J. Soc. Neurosci. 2005;25:10016-10024.

    Not in our library10.1523/jneurosci.2520-05.2005

  259. 259.

    Seidel K., Helmeke C., Poeggel G., Braun K. Repeated neonatal separation stress alters the composition of neurochemically characterized interneuron subpopulations in the rodent dentate gyrus and basolateral amygdala. Dev. Neurobiol. 2008;68:1137-1152.

    Not in our library10.1002/dneu.20651

  260. 260.
  261. 261.

    Serra M., Pisu M.G., Muggironi M., Parodo V., Papi G., Sari R., Dazzi L., Spiga F., Purdy R.H., Biggio G. Opposite effects of short- versus long-term administration of fluoxetine on the concentrations of neuroactive steroids in rat plasma and brain. Psychopharmacology. 2001;158:48-54.

    Not in our library10.1007/s002130100853

  262. 262.

    Serra M., Pisu M.G., Mostallino M.C., Sanna E., Biggio G. Changes in neuroactive steroid content during social isolation stress modulate GABAA receptor plasticity and function. Brain Res. Rev. 2008;57:520-530.

    Not in our library10.1016/j.brainresrev.2007.06.029

  263. 263.

    Shen Q., Lal R., Luellen B.A., Earnheart J.C., Andrews A.M., Luscher B. Gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic–pituitary–adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Biol. Psychiatry. 2010;68:512-520.

    Not in our library10.1016/j.biopsych.2010.04.024

  264. 264.

    Shen Q., Fuchs T., Sahir N., Luscher B. GABAergic control of critical developmental periods for anxiety- and depression-related behavior in mice. PLoS ONE. 2012;7:e47441.

    Not in our library10.1371/journal.pone.0047441

  265. 265.

    Shirayama Y., Muneoka K., Fukumoto M., Tadokoro S., Fukami G., Hashimoto K., Iyo M. Infusions of allopregnanolone into the hippocampus and amygdala, but not into the nucleus accumbens and medial prefrontal cortex, produce antidepressant effects on the learned helplessness rats. Hippocampus. 2011;21:1105-1113.

    Not in our library10.1002/hipo.20824

  266. 266.

    Shu H.J., Eisenman L.N., Jinadasa D., Covey D.F., Zorumski C.F., Mennerick S. Slow actions of neuroactive steroids at GABAA receptors. J. Neurosci.: Off. J. Soc. Neurosci. 2004;24:6667-6675.

    Not in our library10.1523/jneurosci.1399-04.2004

  267. 267.

    Sickmann H.M., Li Y., Mork A., Sanchez C., Gulinello M. Does stress elicit depression? evidence from clinical and preclinical studies. Curr. Top. Behav. Neurosci. 2014.

    Not in our library10.1007/7854_2014_292

  268. 268.

    Sierra A. Neurosteroids: the StAR protein in the brain. J. Neuroendocrinol. 2004;16:787-793.

    Not in our library10.1111/j.1365-2826.2004.01226.x

  269. 269.

    Strohle A., Romeo E., di Michele F., Pasini A., Yassouridis A., Holsboer F., Rupprecht R. GABAA receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am. J. Psychiatry. 2002;159:145-147.

    Not in our library10.1176/appi.ajp.159.1.145

  270. 270.

    Strohle A., Romeo E., di Michele F., Pasini A., Hermann B., Gajewsky G., Holsboer F., Rupprecht R. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder preliminary results. Arch. Gen. Psychiatry. 2003;60:161-168.

    Not in our library10.1001/archpsyc.60.2.161

  271. 271.

    Surget A., Saxe M., Leman S., Ibarguen-Vargas Y., Chalon S., Griebel G., Hen R., Belzung C. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol. Psychiatry. 2008;64:293-301.

    Not in our library10.1016/j.biopsych.2008.02.022

  272. 272.

    Takesian A.E., Hensch T.K. Balancing plasticity/stability across brain development. Prog. Brain Res. 2013;207:3-34.

    Not in our library10.1016/b978-0-444-63327-9.00001-1

  273. 273.
  274. 274.

    Timmermans W., Xiong H., Hoogenraad C.C., Krugers H.J. Stress and excitatory synapses: from health to disease. Neuroscience. 2013;248:626-636.

    Not in our library10.1016/j.neuroscience.2013.05.043

  275. 275.

    Tokuda K., O’Dell K.A., Izumi Y., Zorumski C.F. Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis. J. Neurosci.: Off. J. Soc. Neurosci. 2010;30:16788-16795.

    Not in our library10.1523/jneurosci.4101-10.2010

  276. 276.

    Tokuda K., Izumi Y., Zorumski C.F. Ethanol enhances neurosteroidogenesis in hippocampal pyramidal neurons by paradoxical NMDA receptor activation. J. Neurosci.: Off. J. Soc. Neurosci. 2011;31:9905-9909.

    Not in our library10.1523/jneurosci.1660-11.2011

  277. 277.

    Torres J.M., Ortega E. Differential regulation of steroid 5alpha-reductase isozymes expression by androgens in the adult rat brain. FASEB J. 2003;17:1428-1433.

    Not in our library10.1096/fj.02-1119com

  278. 278.

    Torres J.M., Ruiz E., Ortega E. Effects of CRH and ACTH administration on plasma and brain neurosteroid levels. Neurochem. Res. 2001;26:555-558.

    Not in our library10.1023/a:1010925331768

  279. 279.

    Tozuka Y., Fukuda S., Namba T., Seki T., Hisatsune T. GABAergic excitation promotes neuronal differentiation in adult hippocampal progenitor cells. Neuron. 2005;47:803-815.

    Not in our library10.1016/j.neuron.2005.08.023

  280. 280.

    Trauger J.W., Jiang A., Stearns B.A., LoGrasso P.V. Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry. 2002;41:13451-13459.

    Not in our library10.1021/bi026109w

  281. 281.

    Tse Y.C., Bagot R.C., Wong T.P. Dynamic regulation of NMDAR function in the adult brain by the stress hormone corticosterone. Front. Cell. Neurosci. 2012;6:9.

    Not in our library10.3389/fncel.2012.00009

  282. 282.

    Ulrich-Lai Y.M., Herman J.P. Neural regulation of endocrine and autonomic stress responses. Nat. Rev. Neurosci. 2009;10:397-409.

    Not in our library10.1038/nrn2647

  283. 283.

    Ulrich-Lai Y.M., Jones K.R., Ziegler D.R., Cullinan W.E., Herman J.P. Forebrain origins of glutamatergic innervation to the rat paraventricular nucleus of the hypothalamus: differential inputs to the anterior versus posterior subregions. J. Comp. Neurol. 2011;519:1301-1319.

    Not in our library10.1002/cne.22571

  284. 284.

    Uzunov D.P., Cooper T.B., Costa E., Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. USA. 1996;93:12599-12604.

    Not in our library10.1073/pnas.93.22.12599

  285. 285.
  286. 286.

    Uzunova V., Sampson L., Uzunov D.P. Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action. Psychopharmacology. 2006;186:351-361.

    Not in our library10.1007/s00213-005-0201-6

  287. 287.

    Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394-1397.

    Not in our library10.1126/science.6267699

  288. 288.

    VanDoren M.J., Matthews D.B., Janis G.C., Grobin A.C., Devaud L.L., Morrow A.L. Neuroactive steroid 3alpha-hydroxy-5alpha-pregnan-20-one modulates electrophysiological and behavioral actions of ethanol. J. Neurosci.: Off. J. Soc. Neurosci. 2000;20:1982-1989.

    Not in our library10.1523/jneurosci.20-05-01982.2000

  289. 289.

    Vashchinkina E., Panhelainen A., Vekovischeva O.Y., Aitta-aho T., Ebert B., Ator N.A., Korpi E.R. GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons. J. Neurosci.: Off. J. Soc. Neurosci. 2012;32:5310-5320.

    Not in our library10.1523/jneurosci.4697-11.2012

  290. 290.

    Verleye M., Akwa Y., Liere P., Ladurelle N., Pianos A., Eychenne B., Schumacher M., Gillardin J.M. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol. Biochem. Behav. 2005;82:712-720.

    Not in our library10.1016/j.pbb.2005.11.013

  291. 291.

    Vialou V., Feng J., Robison A.J., Nestler E.J. Epigenetic mechanisms of depression and antidepressant action. Annu. Rev. Pharmacol. Toxicol. 2013;53:59-87.

    Not in our library10.1146/annurev-pharmtox-010611-134540

  292. 292.

    Wang J.M., Johnston P.B., Ball B.G., Brinton R.D. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J. Neurosci.: Off. J. Soc. Neurosci. 2005;25:4706-4718.

    Not in our library10.1523/jneurosci.4520-04.2005

  293. 293.

    Wang J.M., Liu L., Irwin R.W., Chen S., Brinton R.D. Regenerative potential of allopregnanolone. Brain Res. Rev. 2008;57:398-409.

    Not in our library10.1016/j.brainresrev.2007.08.010

  294. 294.

    Wang J.M., Singh C., Liu L., Irwin R.W., Chen S., Chung E.J., Thompson R.F., Brinton R.D. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA. 2010;107:6498-6503.

    Not in our library10.1073/pnas.1001422107

  295. 295.

    Wang X.D., Rammes G., Kraev I., Wolf M., Liebl C., Scharf S.H., Rice C.J., Wurst W., Holsboer F., Deussing J.M., Baram T.Z., Stewart M.G., Muller M.B., Schmidt M.V. Forebrain CRF(1) modulates early-life stress-programmed cognitive deficits. J. Neurosci.: Off. J. Soc. Neurosci. 2011;31:13625-13634.

    Not in our library10.1523/jneurosci.2259-11.2011

  296. 296.

    Warren B.L., Vialou V.F., Iniguez S.D., Alcantara L.F., Wright K.N., Feng J., Kennedy P.J., Laplant Q., Shen L., Nestler E.J., Bolanos-Guzman C.A. Neurobiological sequelae of witnessing stressful events in adult mice. Biol. Psychiatry. 2013;73:7-14.

    Not in our library10.1016/j.biopsych.2012.06.006

  297. 297.

    Weaver I.C., Cervoni N., Champagne F.A., D’Alessio A.C., Sharma S., Seckl J.R., Dymov S., Szyf M., Meaney M.J. Epigenetic programming by maternal behavior. Nat. Neurosci. 2004;7:847-854.

    Not in our library10.1038/nn1276

  298. 298.

    Wieland S., Lan N.C., Mirasedeghi S., Gee K.W. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-o1-20-one. Brain Res. 1991;565:263-268.

    Not in our library10.1016/0006-8993(91)91658-n

  299. 299.

    Wisden W., Laurie D.J., Monyer H., Seeburg P.H. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J. Neurosci.: Off. J. Soc. Neurosci. 1992;12:1040-1062.

    Not in our library10.1523/jneurosci.12-03-01040.1992

  300. 300.

    Wittmer L.L., Hu Y.F., Kalkbrenner M., Evers A.S., Zorumski C.F., Covey D.F. Enantioselectivity of steroid-induced gamma-aminobutyric acid(A) receptor modulation and anesthesia. Mol. Pharmacol. 1996;50:1581-1586.

    Not in our library

  301. 301.

    Womack M.D., Pyner S., Barrett-Jolley R. Inhibition by alpha-tetrahydrodeoxycorticosterone (THDOC) of pre-sympathetic parvocellular neurones in the paraventricular nucleus of rat hypothalamus. Br. J. Pharmacol. 2006;149:600-607.

    Not in our library10.1038/sj.bjp.0706911

  302. 302.

    Xiao C., Zhou C., Li K., Ye J.H. Presynaptic GABAA receptors facilitate GABAergic transmission to dopaminergic neurons in the ventral tegmental area of young rats. J. Physiol. 2007;580:731-743.

    Not in our library10.1113/jphysiol.2006.124099

  303. 303.

    Young S.Z., Taylor M.M., Bordey A. Neurotransmitters couple brain activity to subventricular zone neurogenesis. Eur. J. Neurosci. 2011;33:1123-1132.

    Not in our library10.1111/j.1460-9568.2011.07611.x

  304. 304.

    Zaki A., Barrett-Jolley R. Rapid neuromodulation by cortisol in the rat paraventricular nucleus: an in vitro study. Br. J. Pharmacol. 2002;137:87-97.

    Not in our library10.1038/sj.bjp.0704832

  305. 305.

    Ziegler D.R., Herman J.P. Local integration of glutamate signaling in the hypothalamic paraventricular region: regulation of glucocorticoid stress responses. Endocrinology. 2000;141:4801-4804.

    Not in our library10.1210/endo.141.12.7949

  306. 306.

    Ziegler D.R., Cullinan W.E., Herman J.P. Organization and regulation of paraventricular nucleus glutamate signaling systems: N-methyl-d-aspartate receptors. J. Comp. Neurol. 2005;484:43-56.

    Not in our library10.1002/cne.20445

  307. 307.

    Zimmerberg B., Kajunski E.W. Sexually dimorphic effects of postnatal allopregnanolone on the development of anxiety behavior after early deprivation. Pharmacol. Biochem. Behav. 2004;78:465-471.

    Not in our library10.1016/j.pbb.2004.03.021

  308. 308.

    Zimmerberg B., Brunelli S.A., Hofer M.A. Reduction of rat pup ultrasonic vocalizations by the neuroactive steroid allopregnanolone. Pharmacol. Biochem. Behav. 1994;47:735-738.

    Not in our library10.1016/0091-3057(94)90181-3

  309. 309.

    Zimmerberg B., Rackow S.H., George-Friedman K.P. Sex-dependent behavioral effects of the neurosteroid allopregnanolone (3alpha, 5alpha-THP) in neonatal and adult rats after postnatal stress. Pharmacol. Biochem. Behav. 1999;64:717-724.

    Not in our library10.1016/s0091-3057(99)00149-5

  310. 310.

    Zorumski C.F., Paul S.M., Izumi Y., Covey D.F., Mennerick S. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci. Biobehav. Rev. 2013;37:109-122.

    Not in our library10.1016/j.neubiorev.2012.10.005

  311. 311.

    Zunszain P.A., Horowitz M.A., Cattaneo A., Lupi M.M., Pariante C.M. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol. Psychiatry. 2013;18:1236-1241.

    Not in our library10.1038/mp.2013.87

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.